<PAGE>
Draft of 3/24/98
----------------
================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
[x] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 (FEE REQUIRED)
For the fiscal year ended December 31, 1997 or
---------------------
[_] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 (NO FEE REQUIRED)
For the transition period from ______ to ________
Commission file number 0-22033
-------------------
WESLEY JESSEN VISIONCARE, INC.
(Exact name of registrant as specified in its charter)
Delaware 36-4023739
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
333 East Howard Avenue, Des Plaines, Illinois 60018-5903
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (847) 294-3000
Securities registered pursuant to Section 12(b) of the Act: Not applicable.
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, par value $.01 per share
-------------------------------------------------------------------
(Title of Class)
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes x No
----- -----
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein and will not be contained, to the
best of the Registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [_]
The aggregate market value of voting stock held by non-affiliates of the
Registrant as of March 24, 1998 at a closing sale price of $34.25 as reported by
the Nasdaq National Market was approximately $417,478,250. Shares of Common
Stock held by each officer and director and by each person who owns or may be
deemed to own 10% or more of the outstanding Common Stock have been excluded
since such persons may be deemed to be affiliates. This determination of
affiliate status is not necessarily a conclusive determination for other
purposes.
As of March 24, 1998, the Registrant had 17,766,656 shares of Common Stock
outstanding.
Documents Incorporated by Reference
Portions of the Registrant's Proxy Statement to be used in connection with
the solicitation of proxies for the Registrant's 1998 Annual Meeting of
Stockholders (the "Proxy Statement") are incorporated by reference in Part III
of this Annual Report of Form 10-K (the "Form 10-K").
================================================================================
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
INDEX TO ANNUAL REPORT ON FORM 10-K
<TABLE>
<CAPTION>
Page No.
--------
PART I
<S> <C> <C>
Item 1. Business 1
Item 2. Properties 15
Item 3. Legal Proceedings 16
Item 4. Submission of Matters to a Vote of Security-Holders 16
Item 4A. Executive Officers of the Registrant 16
PART II
Item 5. Market for the Registrant's Common Equity and
Related Stockholder Matters 18
Item 6. Selected Financial Data 19
Item 7. Management's Discussion and Analysis of Financial
Condition and Results of Operations 19
Item 7A. Quantitative and Qualitative Disclosure About Market Risk 28
Item 8. Financial Statements and Supplementary Data 28
Item 9. Changes in and Disagreements with Accountants on
Accounting and Financial Disclosure 28
PART III
Item 10. Directors and Executive Officers of the Registrant 28
Item 11. Executive Compensation 28
Item 12. Security Ownership of Certain Beneficial Owners and Management 28
Item 13. Certain Relationships and Related Transactions 28
PART IV
Item 14. Exhibits, Financial Statement Schedules and Reports on Form
8-K 28
</TABLE>
<PAGE>
PART I
Item 1. Business.
Market data used throughout this report were obtained from industry
publications and internal Company surveys. Industry publications generally state
that the information contained therein has been obtained from sources believed
to be reliable, but that the accuracy and completeness of such information are
not assured. The Company has not independently verified these market data.
Similarly, internal Company surveys, while believed by the Company to be
reliable, have not been verified by any independent sources.
General
Wesley Jessen VisionCare, Inc. (the "Company" or "Wesley Jessen") is the
leading worldwide developer, manufacturer and marketer of specialty soft contact
lenses, based on its share of the specialty lens market. The Company's products
include cosmetic lenses, which change or enhance the wearer's eye color
appearance; toric lenses, which correct vision for people with astigmatism; and
premium lenses, which offer value-added features such as improved comfort for
dry eyes and protection from UV light. The Company offers a broad range of both
conventional contact lenses, which can typically be used for up to 24 months,
and disposable contact lenses, which are intended to be replaced at least every
two weeks. Founded in 1946 by pioneers in the contact lens industry, the Company
has a long-standing reputation for innovation and new product introductions.
The Company operates primarily in the specialty segment of the soft lens
market. In recent years, in both the clear and specialty lens segments, there
has been a pronounced shift in consumers' preferences toward disposable lenses
and away from conventional lenses, which has led to a significant increase in
contact lens expenditures per wearer. The Company estimates that more than 40%
of U.S. soft lens wearers use disposable lenses, up from 21% in 1993. The
Company also offers a complete line of conventional and disposable clear lenses,
which are positioned as companion products to the Company's cosmetic lenses.
According to an independent research firm, more than 75% of all contact
lens prescribers in the United States offer the Company's products, which
permits the Company to rapidly launch new categories of products. Wesley Jessen
develops proprietary technologies, manufacturing processes and products through
a combination of its in-house staff of more than 50 engineers and scientists and
Company-sponsored research by third-party experts. The Company is among the
largest advertisers in the industry and markets and sells its products to
consumers through the second largest advertising campaign in the industry and to
eyecare practitioners through its 196-person salesforce and network of 76
independent distributors, which together sell the Company's products in more
than 75 countries.
The Company was founded by Drs. Newton K. Wesley and George Jessen, who
went on to pioneer the design, manufacture and fitting techniques of hard
contact lenses. From 1980 to 1995, the Company operated as a wholly owned
subsidiary of Schering-Plough Corporation ("Schering-Plough"). On June 28, 1995,
Bain Capital Inc. ("Bain Capital") and the management acquired the Wesley Jessen
division of Schering-Plough (the "Predecessor") in a leveraged acquisition (the
"Wesley Jessen Acquisition"). On October 2, 1996, the Company acquired the
Barnes-Hind division ("Barnes-Hind") of Pilkington plc (the "Barnes-Hind
Acquisition"). At the time of the acquisition, Barnes-Hind was the third largest
manufacturer of speciality contact lenses in the world, with a leading market
position in premium and toric lenses.
Industry Overview
Industry analysts estimate that over 50% of the world's population needs
some type of corrective eyewear. In the United States alone, there are over 156
million people who require some form of corrective eyewear. Most individuals who
wear contact lenses begin to do so in their early teens and the majority of
wearers are between the
1
<PAGE>
ages of 18 and 39. The Company believes that the number of contact lens wearers
will expand as technology improves the convenience, comfort and fit of contact
lenses, so that lenses provide cost-effective and comfortable vision correction
to a larger segment of the population.
The contact lens industry is large and rapidly growing. In 1997,
manufacturers' sales of contact lenses worldwide totaled $2.2 billion,
representing a compound annual growth rate of 11% from $1.1 billion in 1990.
According to industry analysts, the U.S. market for contact lenses is expected
to grow approximately 10% per year through the year 2000. The Company believes
that market growth outside the United States will likely exceed domestic growth
because of lower contact lens penetration rates internationally. Since 1991, the
number of contact lens wearers in the United States has increased by 4% per year
while revenue per wearer has increased by 5% per year as conventional users have
shifted to more costly specialty and disposable lenses. While the market for
hard contact lenses has been relatively flat since 1991 with approximately 6
million U.S. wearers, the number of people wearing soft contact lenses has grown
at a compound annual growth rate of 6% since that time.
The contact lens industry can be divided into the soft lens portion, which
represents approximately 80% of U.S. wearers, and the hard lens portion
(primarily rigid gas permeable ("RGP")), which represents approximately 20% of
U.S. wearers. Within the soft contact lens market, there are three principal
replacement regimes: conventional, disposable and planned replacement.
Conventional lenses are typically replaced after 12 to 24 months and require
periodic cleaning throughout the life of the lens. Disposable soft contact
lenses were introduced in the late 1980s based on the concept that changing
lenses on a more frequent basis helped to improve comfort, convenience and
health of the eye for many wearers. Disposable lenses are changed as often as
daily or up to every two weeks depending on the product. Planned replacement
lenses are designed to be changed as often as every month or up to every three
months and currently represent a small portion of the overall soft lens market.
The two primary segments within the soft lens market are clear and
specialty. Clear lenses (lenses that do not provide value-added features that
specialty lenses offer) represent approximately 70% of the U.S. soft lens market
and include both conventional and disposable products. Growth in the clear lens
segment has been driven primarily by growth in the population of 14- to 25-year-
olds (the prime age group for new lens wearers), the substitution of soft for
hard contact lenses and the continuous evolution in the contact lens market
toward more frequent replacement of contact lenses.
Specialty lenses represent the remaining 30% of the U.S. soft lens market
and generally command a premium price because they are designed for patients who
have a medical need for a specialized lens or who desire a lens with additional
features. Specialty lenses include cosmetic lenses (which change or enhance the
natural color of eyes while correcting vision), toric lenses (for astigmatics)
and premium lenses that offer protein deposit resistance, improved visual
acuity, enhanced comfort for dry eyes or UV protection. Disposable lenses have
recently been introduced into the specialty segment and are expected to gain
market share. The specialty lens segment of the soft contact lens market has
higher projected growth rates than the clear lens segment. For the period from
1994 to 1997, the number of specialty lens wearers has increased at a rate of
11% per year as compared to a 4% per year increase in the number of clear lens
wearers. The Company believes that continued rapid growth in sales of specialty
lenses will result from (i) the continued trend toward disposables; (ii)
increased awareness among consumers and eyecare practitioners of the value-added
features available with specialty lenses; and (iii) new product innovations,
such as disposable toric contact lenses, new cosmetic designs, UV protection
lenses and effective bifocal contact lenses.
An important characteristic of the contact lens industry is that an
individual's need for corrective eyewear is chronic. The need for vision
correction is often diagnosed at an early age and increases over time. Contact
lenses represent an alternative to eyeglasses, while offering improved
peripheral vision and additional features, such as eyecolor enhancement and UV
protection. Contact lens wearers will typically purchase lenses regularly for
several years.
2
<PAGE>
Contact lenses require a prescription specifying a particular brand of
lenses. Such prescriptions are written by either ophthalmologists or
optometrists referred to in the contact lens industry as "fitters". An
ophthalmologist is a physician with a Doctor of Medicine ("MD") degree who
specializes in eyecare and an optometrist is a state-licensed eyecare specialist
who holds a Doctor of Optometry ("OD") degree. Fitters have the ability to
influence patients' choice of which contact lens brand they will wear.
Therefore, if a contact lens manufacturer successfully markets its products to a
fitter, that fitter will carry that manufacturer's brand of contact lenses in
inventory and offer it to patients. Once the brand is in the fitter's inventory,
the manufacturer will likely receive a stream of revenues from new patients for
whom the brand is prescribed as well as from patients who are refitted, change
lens types or need different prescriptions. Also, the manufacturer will be more
likely to successfully place new products in the fitter's inventory.
Prescriptions for contact lenses are filled by either ophthalmologists,
optometrists, optical chains, health maintenance organizations (HMOs),
pharmacies or mail order houses.
The contact lens industry is characterized by high brand loyalty. The
Company believes that wearers resist switching brands once a particular brand is
prescribed and fitted successfully. By staying with an existing brand, a
customer can replace his or her current lens without an eye examination. Even
for an adjusted prescription, customers typically acclimate to a particular lens
design and may experience discomfort if refitted with a new brand. Typically,
only when a customer is experiencing difficulty with a lens or the customer
wants to switch from conventional to disposable lenses or from clear to
specialty lenses will a fitter refit with a different brand of lens. The Company
believes, based on historical patterns in the contact lens industry that once a
product category has matured, brand loyalty causes competitive market share to
remain relatively constant. However, overall market share may shift because of
different growth rates of each category or the creation of new categories.
No new significant competitors have entered the soft contact lens industry
in the last ten years. To compete successfully in the industry entails
substantial risks and requires significant investment of time and resources. In
particular, the Company believes a new entrant must successfully (i) develop
innovative product offerings; (ii) master the sophisticated processes required
to manufacture contact lenses; (iii) invest the significant capital required to
develop manufacturing capacity; (iv) overcome existing patent protections
covering the design, materials and manufacturing processes of contact lenses;
and (v) obtain FDA product clearances, each of which may take several years.
Products
The following table sets forth the approximate composition, by product
line, of the Company's net sales for the year ended December 31, 1997:
Net Sales by Product Line
(dollars in thousands)
<TABLE>
<CAPTION>
Year Ended
-------------------
Product Line December 31, 1997
- - ------------ -------------------
Amount Percent
--------- --------
<S> <C> <C>
Specialty Lenses $227,495 81%
Clear Lenses 45,444 16%
Hard/Other Lenses 9,239 3%
-------- ---
Total Lenses $282,178 100%
======== ===
</TABLE>
3
<PAGE>
Specialty Lenses. The Company's products primarily consist of specialty
soft contact lenses, including cosmetic, toric and premium lenses. With the
broadest product offering in the industry, the Company captured nearly 38% of
the U.S. specialty lens segment in 1997. The Company's specialty soft contact
lens products include the following:
Cosmetic Lenses. Cosmetic lenses enhance or change the color of a wearer's
eyes. The Company's opaque color lenses, which change the color of dark eyes
(e.g., brown to green), utilize a patented dot matrix technology that the
Company believes allows for superior cosmetic appeal. As a result, the Company's
opaque cosmetic lens products have become the standard in the market. In early
1996, the Company introduced its new enhancer color lenses, which enhance the
natural color of light eyes and which the Company believes will become the
market standard due to its patented color printing process that allows the
pupil-covering zone of the lens to remain clear. The Company manufactures a
complete line of cosmetic lenses, including: (i) the conventional DuraSoft 2
daily wear lens, which is removed and cleaned daily and typically is replaced
after 12 to 24 months; (ii) the conventional DuraSoft 3 extended wear lens,
which can be worn overnight for up to seven days and is also typically replaced
after 12 to 24 months; and (iii) the disposable FreshLook contact lens, which is
typically replaced every two weeks. With the broadest product offering in the
cosmetic lens segment, the Company captured over 55% of the U.S. cosmetic lens
market in 1997.
Toric Lenses. Toric lenses are designed to correct vision for people with
astigmatism, which is characterized by an irregularly shaped cornea. Prior to
the introduction of the Company's toric lenses and other competing products in
the late 1980s, this condition was not effectively correctable through the use
of soft contact lenses. In February 1997, the Company introduced a toric version
of its enhancer colored lenses. Approximately 30% of the U.S. population
requiring vision correction are diagnosed with astigmatism, of which only 5%
currently wear soft contact lenses. The Company's Optifit, Hydrocurve and CSI
toric lenses captured approximately 25% of the U.S. toric lens market in 1997.
Premium Lenses. Premium lenses offer the wearer value-added features such
as protein deposit resistance, improved visual acuity, enhanced comfort for dry
eyes and UV protection. The Company manufactures the premium CSI lens, which has
long been regarded by eyecare practitioners and optical retailers as having
superior visual acuity and deposit resistance. The Company also recently
repositioned Precision UV, the first disposable lens available with UV
protection, which is quickly gaining share from many clear disposable lenses.
The Company's market research suggests that some 90% of contact lens wearers are
interested in lenses offering UV protection. The Company's Gentle Touch product,
which is typically replaced every three months, was the first lens designed
specifically for and approved by the FDA for use without intensive cleaning or
special handling required of conventional lenses and offers the unique
combination of enhanced comfort for dry eyes, deposit resistance and low cost
relative to disposable alternatives. The Company captured 90% of the U.S.
premium lens segment in 1997.
4
<PAGE>
The following table sets forth certain of the brand names under which the
Company's specialty contact lenses are sold:
Type of Lens Specialty Contact Lens
-------------- ----------------------------------------------
Cosmetic Toric Premium
------------------- ----------- ------------
Conventional: DuraSoft CSI Aquaflex
Elegance (a) Optifit CSI Clarity
Natural Touch (a) Hydrocurve Hydrocurve
Wild Eyes novelty
Disposable/ Planned Replacement:
FreshLook Colors FreshLook Gentle Touch
FreshLook Enhancers Precision UV
(a) Used only in international markets.
The Company has successfully entered into the private label market with the
offering of a private label UV protection lens. The Company sells its specialty
contact lenses under private label primarily in Japan, the United Kingdom,
Canada and France. The Company believes that the private label market offers
significant growth opportunities due to the Company's unique product offerings
and low-cost manufacturing capabilities.
Clear Lenses. Wesley Jessen manufactures a complete line of conventional
and disposable clear lenses that are positioned as companion lenses to the
DuraSoft and FreshLook cosmetic product lines. The Company believes that eyecare
practitioners can increase their revenues and profitability, as well as the
value provided to lens wearers, by fitting patients with either a DuraSoft or
FreshLook clear or cosmetic lens and then selling the patient a companion
cosmetic or clear lens with no additional fitting expense. In fact,
approximately 70% of color lens wearers also own clear lenses.
Hard/Other Lenses. The Company also sells Polycon RGP lenses to a large
base of eyecare practitioners who fit RGP lenses. In addition, the Company
manufactures prosthetic lenses, which are custom cosmetic products that return
damaged or disfigured eyes to normal appearance. The Company donates all profits
generated from its prosthetic product line to professional associations to
generate goodwill with eyecare practitioners.
Research and Development
The Company's research and development efforts are focused on product
development and process technology to support its specialty lens business. The
Company maintains a core research and development staff of over 50 engineers and
scientists, which oversees the Company's research projects. Such projects are
generally conducted by independent laboratories and universities at the
Company's direction and expense. The Company's research and development expenses
totaled $12.0 million, or 4.3% of net revenues, for the year ended December 31,
1997.
In the last twelve months, the Company has introduced four new products or
line extensions, including colored toric lenses, custom toric and color lenses
and expanded cosmetic powers and colors. The Company also developed an improved,
patented UV protection specialty lens for which it received FDA approval in
January 1996. The UV protection lens allows the Company to further penetrate the
emerging health-conscious market and permits cross-promotion with the Company's
current specialty lens wearers.
5
<PAGE>
The Company has a history of innovation and new product introductions. The
Company is currently investing in the development of, among other specialty
products, a disposable toric lens, a next generation cosmetic lens, and a new
disposable UV-protection lens. The Company is also investing in the development
of bifocal contact lenses (for persons, typically over age 45, who experience
both farsightedness and nearsightedness) and has received several patents
related to its bifocal lens technology. In the contact lens industry, no
products currently being marketed in the bifocal category have achieved
widespread commercial acceptance, and as a result, the Company believes that a
significant market opportunity is available to the Company if it can harness its
capabilities to successfully launch bifocal contact lenses. Finally, the Company
has targeted additional research and development projects to cut manufacturing
costs in the cosmetic, premium and toric product lines.
Manufacturing
Substantially all of the Company's products are manufactured in the
Company's four principal production facilities, which are located in Cidra,
Puerto Rico; Des Plaines, Illinois; San Diego, California; and Southampton,
United Kingdom. See "--Properties." The Company utilizes state-of-the-art
manufacturing equipment and process technology to control the quality of its
products and to minimize costs. The Company engages in manufacturing processes
that are designed to handle short production runs. As a result, the Company
believes that it enjoys a competitive advantage over other contact lens
manufacturers because it can be more versatile and cost-competitive in market
segments that require special features and products manufactured to meet more
stringent specifications. The Company's disposable lens manufacturing facilities
are currently operating at approximately 70% of their maximum capacity and have
sufficent capacity to meet the Company's needs for several years.
The Company produces its hard and soft contact lens products primarily
through manufacturing processes known as lathing and cast molding. Lathing is a
machining process through which a piece of rigid lens material is shaped into a
concave form with refractive characteristics by using a high-precision lathe.
Following this machining, soft lenses are hydrated in a saline solution and
sterilized, while RGP lenses are produced using polymers that do not absorb
moisture and do not require sterilization. Lathing technology is particularly
well suited for use in short production runs and is used by the Company to
produce soft lenses at its Cidra, Puerto Rico; San Diego, California; and
Southampton, United Kingdom facilities and to produce RGP lenses at its Atlanta,
Georgia and Farnham, United Kingdom facilities.
The Company also uses cast molded technology to produce its disposable
contact lenses. In this process, a disposable plastic mold is made through the
use of an automated injection molding press containing highly-engineered optical
tooling. A liquid monomer is then dispensed into the mold which polymerizes to
form the lens. In dry cast molding, the lenses are formed in a rigid state and
are hydrated to their final characteristics after being removed from the mold.
In wet cast molding, the lenses are formed fully hydrated. The Company uses dry
cast molded technology at its Southampton, United Kingdom facility and wet cast
molded technology at its Des Plaines, Illinois facility.
Sales and Marketing
The Company has implemented a two-pronged sales and marketing strategy that
reflects the Company's belief that both consumers and eyecare practitioners are
important to the success of the Company's products. To generate consumer
awareness and increase demand for its products, the Company has spent
approximately $10 million in 1997 on a national advertising campaign featuring
Christy Turlington. In total, the Company spent approximately $20 million
worldwide during 1997 for the advertisement and promotion of its disposable
cosmetic lenses. The Company also has developed cross-promotion programs
designed to increase sales of its cosmetic lenses by offering a set of the
Company's most popular cosmetic lenses with each purchase of a set of six pairs
of clear disposable lenses.
6
<PAGE>
Due to the fitter's influence over a patient's choice of contact lens
brand, the Company believes that developing and maintaining strong relationships
with eyecare practitioners is the most critical aspect of its sales and
marketing strategy. The Company has a salesforce of 196 persons who market the
Company's products to eyecare practitioners. The Company's salesforce seeks to
train new ODs and MDs to fit the Company's lenses and to inform them of the
revenue potential and value-added features of the Company's products. In
marketing to eyecare practitioners, the Company stresses the quality and
features offered by its products, the breadth of its product line and the
ability of such practitioners to generate more revenue per patient by offering
the Company's value-added products. The Company also advertises its products to
eyecare practitioners through promotional materials, trade publications and
conventions.
The Company currently sells through a direct salesforce in North America,
Europe and Australia. Countries in Europe, Asia and Latin America not directly
served by the Company are serviced by a broad network of distributors. The
Barnes-Hind Acquisition strengthened the Company's global distribution
infrastructure by contributing direct salesforces in Germany, Spain, Belgium,
Netherlands, Luxembourg and Australia, in addition to strengthening existing
salesforces in the United States, France, Italy, Canada and the United Kingdom.
The following table sets forth the Company's net sales to the geographic
regions indicated for the year ended December 31, 1997:
Net Sales to Geographic Regions
(dollars in thousands)
<TABLE>
<CAPTION>
Region Amount Percent
----------------------------- -------- -------
<S> <C> <C>
United States................................. $160,420 57%
Rest of World................................. 121,758 43%
-------- -----
Total....................................... $282,178 100.0%
======== =====
</TABLE>
See Note 15 to Notes to Consolidated Financial Statements for information
relating to the Company's international operations.
Customers
The Company currently sells its products through a variety of channels
including fitters and distributors who sell to fitters and lens-replacement
suppliers. The Company sells to a highly fragmented account base with no one
customer accounting for more than 5% of its revenues for the year ended December
31, 1997. Furthermore, the Company's top 10 customers accounted for less than
25% of its revenues for the year ended December 31, 1997.
In the United States, the Company sells to three customer segments: private
practitioners, chain accounts and distributors. There are approximately 17,700
private practitioners (MDs and ODs not affiliated with a retail chain) who fit
the Company's products. In addition, the Company has distribution in over 5,000
retail chain locations, such as Cole National Corporation, LensCrafters,
National Vision Association and Wal-Mart Stores, Inc., that advertise, promote
and fill prescriptions for the Company's products. Distributors supply but do
not fit the Company's lenses. The chart below illustrates the mix of
distribution channels used by Wesley Jessen in the United States in 1997:
7
<PAGE>
Net Sales by Distribution Channel
(as a percentage of net sales)
<TABLE>
<CAPTION>
Percent of 1997
---------------
Distribution Channel U.S. Sales
-------------------- ----------
<S> <C> <C>
Private Practitioners............................. 50%
Chain Accounts.................................... 16%
Distributors...................................... 34%
---
Total....................................... 100%
===
</TABLE>
In Europe, key corporate accounts like Boots and D&A in the United Kingdom
and Optic 2000 in France have selected the Company's lenses as their private
label as well as offering its branded products. In Japan, the world's second
largest contact lens market, the Company has formed strategic relationships with
five of the leading hard and soft contact lens manufacturers. The Company has
doubled its Japanese sales in the last year using this strategy.
The Barnes-Hind Acquisition provided Wesley Jessen with access to a new set
of accounts and the opportunity to cross-sell existing product lines between
Wesley Jessen's and Barnes-Hind's extensive customer bases.
Distribution
The Company performs most warehousing, inventory management, order taking
and order fulfillment functions in-house. The Company's fulfillment system
provides the flexibility to receive, fill and ship orders as small as a single
lens and as large as a full truckload. Approximately 8,500 orders are received
daily, primarily by telephone and facsimile in seven customer service centers in
North America, Europe, Japan and Australia.
In the U.S., approximately 66% of the Company's lenses are shipped
primarily by common carriers directly to eyecare practitioners from distribution
centers in San Diego, California and Des Plaines, Illinois. The remaining 34%
are shipped to distributors, who resell lenses to practitioners and mail-order
houses. In several key markets outside the U.S., the Company sells and
distributes lenses directly to eyecare practitioners. In other international
markets, the Company serves customers through its network of 76 independent
distributors.
Competition
The contact lens market is highly competitive. The Company faces
competition from other companies within each segment of the contact lens market
in which it operates. In the specialty segment of the market, the Company
principally competes with divisions of large medical and pharmaceutical
companies, including Ciba Vision (a division of Novartis Corporation) and Bausch
& Lomb, Inc. as well as with smaller companies. To the extent the Company
operates in the clear lens segment, it faces competition primarily from Vistakon
(a division of Johnson & Johnson) and other large contact lens manufacturers
such as Ciba Vision and Bausch & Lomb, Inc. Certain of the Company's competitors
in each segment have lower costs of operations, products with enhanced features,
substantially greater resources to invest in product development and customer
support, greater vertical integration and greater access to financial and other
resources than the Company. While the Company is the leading manufacturer and
distributor of specialty contact lenses, the Company ranks fourth in the contact
lens market overall in terms of net revenues. To a lesser extent, the Company
also competes with manufacturers of eyeglasses and providers of other methods of
vision correction, including refractive surgical procedures.
Within the contact lens market, the Company believes that the principal
competitive factors in the specialty segment include product innovation, brand
awareness, product quality and price. Due to the manner in
8
<PAGE>
which contact lenses are distributed (i.e., through prescription), the Company
also competes on the basis of its relationships and reputation with eyecare
practitioners.
Suppliers
The Company has a broad base of suppliers. The Company has qualified
multiple vendors to supply substantially all of the materials used by the
Company in its manufacturing processes and actively seeks to qualify new vendors
to insure adequate access to such materials. The primary raw materials used by
the Company in the production of contact lenses are specialty chemicals. For the
year ended December 31, 1997, no supplier accounted for more than 5% of the
Company's costs of goods sold.
The Company utilizes a number of advanced polymers and other sophisticated
materials in the production of its contact lenses. Due to the highly technical
and specialized nature of certain of its production materials, the Company
relies from time to time on single suppliers to provide it with sufficient
quantities of certain materials used in the production of one or more of its
product lines. To minimize its reliance on a particular vendor, the Company
continually seeks to identify multiple vendors qualified to supply its
production materials. Although the Company believes that it is not dependent on
any single supplier, the inability of the Company to obtain sufficient
quantities of certain production inputs could have a material adverse effect on
the Company's financial condition or results of operations.
Patents and Trademarks
The Company's business and competitive position benefit from the validity
and enforcement of its intellectual property protection. The Company owns a
variety of patents, trademarks, trade secrets, know-how and other intellectual
property which it believes to be important to its current and future success.
The market for the Company's products rewards product innovation, which tends to
amplify the importance of intellectual property protection.
The Company holds numerous U.S. and foreign patents and patent applications
which relate to aspects of the technology used in the Company's products. The
Company's policy is to file patent applications to protect technology,
inventions and improvements that are considered important to the development of
its business. There can be no assurance that patent applications filed by the
Company will result in the issuance of patents or that any of the Company's
intellectual property will continue to provide competitive advantages for the
Company's products or will not be challenged, circumvented by others or
invalidated.
The Company holds more than 70 U.S. patents, many of which have been
extended into key foreign countries. The most important part of the Company's
patent portfolio relates to the design and production techniques of the
Company's cosmetic lenses. These patents begin to expire in the year 2004. The
Company's patents include patterns for changing the color of and enhancing the
iris, as well as methods for performing the printing operation and promoting the
adhesion of the printed ink to the lens. This group of patents covers both the
technology used by the Company in the production of its cosmetic lenses, as well
as many viable alternatives which could be used to replicate such production
techniques. Another important group of patents covers the Company's newest lens
molding technology, which accommodates a high degree of automation with
correspondingly lower manufacturing cost. The features covered are casting cup
design, numerous process techniques and blister package design. The Company has
filed but not yet received a patent for its automatic lens inspection system.
The Company also holds patents covering a UV-absorbing lens and a proprietary
compound for making such lenses, the design and manufacture of toric lenses,
lens materials and bifocal lens technology.
The Company's policy is to aggressively prosecute and defend its patents
and other proprietary technology. The Company is currently seeking to enforce
its intellectual property rights to cosmetic lenses in lawsuits pending in
Italy. The prosecution and defense of intellectual property protections, like
any lawsuit, is inherently uncertain and carries no guarantee of success. The
protection of intellectual property in certain foreign countries is
9
<PAGE>
particularly uncertain. There can be no assurance that the prosecution and
defense of its intellectual property will be successful or that the Company will
be able to secure adequate intellectual property protections in the future.
The Company's trademarks include the following well recognized brand names:
Aquaflex(R), CSI(R), DuraSoft(R), Elegance, FreshLook(R), Gentle Touch,
Hydrocurve, Optifit(R), Polycon(R), Precision UV and SoftPerm(R). The Company's
policy is to register trademarks in countries where registration is available
and deemed necessary or appropriate. Trademark applications are pending for
various marks in the United States and other countries. There are gaps in
registrations, and some marks may not be available for use in various countries.
In addition to patents and trademarks, the Company owns certain trade
secrets, copyrights, know-how and other intellectual property. The Company seeks
to protect these assets, in part, by entering into confidentiality agreements
with its business partners, consultants and vendors and appropriate non-
competition agreements with its officers and employees. There can be no
assurance that these agreements will not be breached, that the Company will have
adequate remedies for any such breach or that the Company's trade secrets and
other intellectual property will not otherwise become known or be independently
developed by others and thereby become unprotected.
Government Regulation
The Company's products are generally regulated in the United States and in
foreign countries as medical devices. As a manufacturer of medical devices,
the Company is subject to regulation in the United States by the Food and Drug
Administration (the "FDA") and corresponding state and foreign regulatory
agencies where the Company sells its products. These regulations generally
govern the introduction of new medical devices, the maintenance of certain
records, the tracking of devices and other matters. The regulatory environment
in which the Company operates can be expensive, time-consuming and uncertain.
FDA Regulation
Pursuant to the Federal Food, Drug and Cosmetic Act (the "FDC Act"), and
the regulations promulgated thereunder, the FDA regulates the preclinical and
clinical testing, manufacture, labeling, distribution, and promotion of medical
devices.
Noncompliance with applicable requirements can result in, among other
things, fines, injunctions, civil penalties, recall or seizure of products,
total or partial suspension of production, failure of the government to grant
premarket clearance or premarket approval for devices, withdrawal of marketing
clearances or approvals and criminal prosecution. The FDA also has the authority
to request the recall, repair, replacement or refund of the cost of any device
manufactured or distributed by the Company.
Under the FDC Act, clearance or approval by the FDA is required prior to
the commercialization of a medical device. The FDA classifies medical devices as
Class I, Class II or Class III, depending on the nature of the medical device
and the existence in the market of any similar devices. The nature of the
clearance or approval procedures is dependent on the classification of the
medical device in question. Class I medical devices are subject to general
controls, including labeling, premarket notification and adherence to the FDA's
good manufacturing practice regulations (''GMP Regulations''). Class II medical
devices are subject to general and special controls, including performance
standards, postmarket surveillance, patient registries and FDA guidelines. Class
III medical devices are those which must receive premarket approval by FDA to
ensure their safety and effectiveness, are generally life-sustaining, life-
supporting devices or implantable devices or new devices which have been found
not to be substantially equivalent to currently marketed medical devices. The
Company's products are generally regulated as Class II medical devices, with
some products (extended wear lenses) regulated as Class III medical
devices.
10
<PAGE>
Before a new device can be introduced into the U.S. market, it must receive
from the FDA clearance or approval, either premarket notification clearance
under Section 510(k) of the FDC Act or approval pursuant to the more costly and
time-consuming PMA procedure. The Company's daily wear contact lenses are
generally subject to the 510(k) clearance procedure while its extended wear
contact lenses are subject to the PMA requirements. A PMA application must be
supported by valid scientific evidence to demonstrate the safety and
effectiveness of the device, typically including the results of clinical trials,
bench tests, laboratory and animal studies. The PMA must also contain a complete
description of the device and its components, and a detailed description of the
methods, faculties and controls used to manufacture the device. In addition, the
submission must include the proposed labeling, advertising literature and any
training materials. The PMA process can be expensive, uncertain and lengthy, and
a number of devices for which FDA approval has been sought by other companies
have never been approved for marketing. Modifications to a device that is the
subject of an approved PMA, its labeling, or manufacturing process may require
approval by the FDA of PMA supplements or new PMAs. Supplements to a PMA often
require the submission of the same type of information required for an initial
PMA, except that the supplement is generally limited to that information needed
to support the proposed change from the product covered by the original PMA.
A 510(k) clearance will be granted if the submitted information establishes
that the proposed device is "substantially equivalent" to a legally marketed
Class I or Class II medical device or a Class III medical device for which the
FDA has not called for PMAs. For any devices that are cleared through the 510(k)
process, modifications or enhancements that could significantly affect safety or
effectiveness, or constitute a major change in the intended use of the device,
will require new 510(k) submissions. While less expensive and time-consuming
than obtaining PMA clearance, securing 510(k) clearance may involve the
submission of a substantial volume of data, including clinical data, and may
require a substantive review of six months or more. The Company markets contact
lenses which have received 510(k) clearances as well as lenses which have been
the subject of approved PMA applications.
Any products manufactured or distributed pursuant to 510(k) clearance or an
approved PMA are subject to pervasive and continuing regulation by the FDA,
including recordkeeping requirements and reporting of adverse experience with
the use of the device.
The Company currently has over 20 PMAs and 510(k) clearances for its
products marketed in the United States. New products may require clinical
studies to support a PMA or 510(k) clearance. There is no certainty that
clinical studies involving new products will be completed in a timely manner or
that the data and information obtained will be sufficient to support the filing
of a PMA or 510(k) clearance. There can be no assurance that the Company will be
able to obtain necessary approvals to market new devices or any other products
under development on a timely basis, if at all, and delays in receipt or failure
to receive such approvals, the loss of previously received approvals, or failure
to comply with existing or future regulatory requirements could have a material
adverse effect on the Company's business, financial condition and results of
operations.
The Company has made modifications to its devices which the Company
believes do not require the submission of new 510(k) notices or PMA supplements.
There can be no assurance, however, that the FDA would agree with any of the
Company's determinations not to submit a new 510(k) notice or PMA supplement for
any of these changes or would not require the Company to submit a new 510(k)
notice or PMA supplement for any of the changes made to the device. If the FDA
requires the Company to submit a new 510(k) notice or PMA supplement for any
device modification, the Company may be prohibited from marketing the modified
device until the 510(k) notice or PMA supplement is cleared by the FDA. There
can be no assurance that future clearances or approvals, whether under the
510(k) clearance procedure or the PMA procedure, will be obtained in a timely
fashion or at all. The failure to obtain such clearances or approvals in a
timely fashion or at all could have a material adverse effect on the Company's
business, financial condition or results of operations.
If human clinical trials of a device are required, whether for a 510(k) or
a PMA, and the device presents a "significant risk," the sponsor of the trial
(usually the manufacturer or the distributor of the device) is required to
11
<PAGE>
file an investigational device exemption (''IDE'') application prior to
commencing human clinical trials. IDE regulations generally require FDA approval
and approval by an independent institutional review board before a clinical
study may begin. Conforming with IDE regulations can add significant cost and/or
delay to the process of obtaining FDA approval for a medical device. Submission
of an application IDE does not give assurance that the FDA will approve the IDE
application and, if it is approved, there can be no assurance that the FDA will
determine that the data derived from these studies support the safety and
efficacy of the device or warrant the continuation of clinical studies. Sponsors
of clinical trials are permitted to sell investigational devices distributed in
the course of the study provided such compensation does not exceed recovery of
the costs of manufacture, research, development and handling. An IDE supplement
must be submitted to and approved by the FDA before a sponsor or investigator
may make a change to the investigational plan that may affect its scientific
soundness or the rights, safety or welfare of human subjects.
As a manufacturer of medical devices, the Company is required to register
with the FDA and comply with the FDA's good manufacturing practice regulations.
GMP Regulations require that the Company manufacture its products and maintain
its manufacturing, testing and control activities records in a prescribed
manner. Further, the Company is required to comply with FDA requirements for
labeling and promoting its products. The Company is subject to periodic
inspections by the FDA and can be subjected to a number of regulatory actions if
it is found not to be in compliance with applicable laws and regulations. If the
FDA believes that a company may not be operating in compliance with applicable
laws and regulations, it can record its observations on a form FDA 483; place
the company under observation and reinspect the facilities; institute
proceedings to issue a warning letter apprising of violative conduct; detain or
seize products; mandate a recall; enjoin future violations; and assess civil and
criminal penalties against the company, its officers or its employees. In
addition, clearances or approvals could be withdrawn in appropriate
circumstances. Failure to comply with regulatory requirements or any adverse
regulatory action could have a material adverse affect on the Company. On
occasion, the Company has received notifications from the FDA of alleged
deficiencies in the Company's compliance with FDA requirements. The Company's
San Diego, California; Southampton, United Kingdom; Cidra, Puerto Rico; and Des
Plaines, Illinois facilities have been inspected within the past two years. Two
form FDA 483s were issued. The Company responded to one such form with
corrective action which the FDA accepted. In March 1996, the Company objected to
the other form as unfounded. The Company has received no further communications
from the FDA on such matter. The Company does not expect such inspections to
give rise to any material FDA compliance issues or to otherwise have a material
adverse effect on the Company.
Manufacturers of medical devices for marketing in the United States must
also comply with medical device reporting (''MDR'') requirements that a firm
report to FDA any incident in which its product may have caused or contributed
to a death or serious injury, or in which its product malfunctioned and, if the
malfunction were to recur, it would be likely to cause or contribute to a death
or serious injury. Labeling and promotional activities are subject to scrutiny
by the FDA and, in certain circumstances, by the FTC. Current FDA enforcement
policy prohibits the marketing of approved medical devices for unapproved uses.
The Company is subject to routine inspection by the FDA and certain state
agencies for compliance with GMP requirements, MDR requirements, and other
applicable regulations. The FDA has recently finalized changes to the GMP
regulations, including the addition of design control requirements, which will
likely increase the cost of compliance with GMP requirements. There can be no
assurance that the Company will not incur significant costs to comply with laws
and regulations in the future or that laws and regulations will not have a
material adverse effect upon the Company's business, financial condition or
results of operation. The Company believes that all of its products offered for
sale have received all required FDA approvals or clearance, and that it is in
substantial compliance with FDA regulations, including GMP and MDR requirements.
International Regulation
The Company's products are also subject to regulation in other countries in
which it sells its products. The laws and regulations of such countries range
from comprehensive medical device approval procedures such as
12
<PAGE>
those described above to simple requests for product data or certifications. The
number and scope of these laws and regulations are increasing. In particular,
medical devices in the EU are subject to the EU's new medical devices directive
(the "Directive").
Under the system established by the Directive, all medical devices other
than active implants and in vitro diagnostic products must qualify for CE
marking by June 14, 1998. "CE marking" means the manufacturer certifies that
its product bearing the CE mark satisfies all requirements essential for the
product to be considered safe and fit for its intended purpose. During the
transitional period (from January 1, 1995 to June 14, 1998) medical devices can
be placed on the market and put into service if they comply with the
requirements of the Directive or national requirements that were in force on
December 31, 1994.
In order to qualify for CE marking, the manufacturer must comply with the
"Essential Requirements" of the Directive, relating to the safety and
performance of the product. In order to demonstrate compliance, a manufacturer
is required to undergo a conformity assessment, which includes assessment of the
manufacturer's quality assurance system by self-selected certification
organizations referred to as a "Notified Body." After all necessary conformity
assessment tests have been completed to the satisfaction of the Notified Body
and the manufacturer is convinced that it is in full compliance with the
Directive, CE marking may be affixed on the products concerned. The Company has
undergone such conformity assessment, with two Dutch and one British non-
governmental entities chosen by the Company as its Notified Bodies. The Company
has received CE marking authorization for all products it currently markets in
the EU.
Although member countries must accept for marketing medical devices bearing
a CE marking without imposing further requirements related to product safety and
performance, each country may require the use of its own language or labels and
instructions for use. "National Competent Authorities" who are required to
enforce compliance with the requirements of the Directive, can restrict,
prohibit and recall CE-marked products if they are unsafe. Such a decision must
be confirmed by the European Commission in order to be valid. Member countries
can impose additional requirements as long as they do not violate the Directive
or constitute technical barriers to trade.
Additional approvals from foreign regulatory authorities may be required
for international sale of the Company's products in non-EU countries. Failure to
comply with applicable regulatory requirements can result in the loss of
previously received approvals and other sanctions and could have a material
adverse effect on the Company's business, financial condition and results of
operations.
Additional Regulation
The Company also is subject to numerous federal, state and local laws
relating to such matters as safe working conditions, manufacturing practices,
environmental protection, fire hazard control and disposal of hazardous or
potentially hazardous substances. There can be no assurance that the Company
will not be required to incur significant costs to comply with such laws and
regulations in the future or that such laws or regulations will not have a
material adverse effect upon the Company's ability to do business.
The Company's success depends to a significant extent upon the success of
its customers in the retail optical industry. These customers are subject to a
variety of federal, state and local laws, regulations and ordinances, including
those regarding advertising, location and design of stores, products sold and
qualifications and practices of the industry. The state and local legal
requirements vary widely among jurisdictions and are subject to frequent change.
Furthermore, numerous health-care related legislative proposals have been made
in recent years in the United States Congress and in various state legislatures.
The potential impact of these proposals with respect to the business of the
Company's customers is uncertain, and there is no assurance that the proposals,
if adopted, would not have a material adverse impact on the Company.
13
<PAGE>
Employees
As of December 31, 1997, the Company had approximately 2,820 full-time and
part-time employees, including 1,785 in the United States (including Puerto
Rico), 970 in Europe, and 68 in the rest of the world. The Company has no
collective bargaining agreements with any union and believes that its overall
relations with employees are satisfactory.
Environmental, Health and Safety Matters
The Company is subject to federal, state, local and foreign environmental
laws and regulations and is subject to liabilities and compliance costs
associated with the past and current handling, processing, storing and disposing
of hazardous substances and wastes. The Company's operations are also subject to
federal, state and local occupational health and safety laws and regulations.
The Company devotes resources to maintaining environmental regulatory compliance
and managing environmental risk and believes that it conducts its operations in
substantial compliance with applicable environmental and occupational health and
safety laws and regulations. The Company does not expect to incur material
capital expenditures for environmental controls in the current or succeeding
fiscal year.
In connection with the Wesley Jessen Acquisition and the Barnes-Hind
Acquisition, the respective sellers, subject to certain limitations, agreed to
retain responsibility for, and indemnify the Company from and against, certain
environmental matters. These matters include addressing a limited area of
historical contamination at the Company's Des Plaines facility and settling any
liability of Barnes-Hind at a Superfund site located in Whittier, California.
Notwithstanding these contractual agreements, the Company could be pursued in
the first instance by governmental authorities or third parties with respect to
certain indemnified matters, subject to the Company's right to seek
indemnification from the appropriate seller. Management does not currently
believe that any such matter will have a material adverse effect on the business
or financial condition of the Company.
14
<PAGE>
Item 2. Properties.
The Company's principal manufacturing facilities are located in Cidra,
Puerto Rico; Des Plaines, Illinois; San Diego, California; and Southampton,
United Kingdom. Following the Wesley Jessen Acquisition, the Company's
headquarters were relocated from Chicago to its facility in Des Plaines,
Illinois (a suburb of Chicago). In Europe, Barnes-Hind has consolidated
warehouses and customer service centers into one distribution center in the
United Kingdom and two customer service centers in the United Kingdom and
France. In addition, the former corporate headquarters of Barnes-Hind, which was
located in Sunnyvale, California, was closed in the third quarter of 1997.
The Company believes that substantially all of its property and production
equipment is in good condition and that it has sufficient capability to meet its
current and projected manufacturing and distribution needs for the foreseeable
future. All of the Company's owned properties are subject to a mortgage as
collateral under the Bank Credit Agreement. The following table describes the
principal properties of the Company as of December 31, 1997:
<TABLE>
<CAPTION>
Square Owned/
Location Function Footage Leased
- - -------- -------- ------- ------
<S> <C> <C> <C>
Des Plaines, Illinois Corporate Headquarters/Disposable 340,000 Owned
Manufacturing/R&D/Distribution
Chicago, Illinois Distribution Center (1) 48,000 Leased
San Diego, California Conventional Manufacturing 19,000 Owned
San Diego, California Conventional Manufacturing/Distribution 117,700 Leased
Atlanta, Georgia RGP Manufacturing 7,200 Leased
Cidra, Puerto Rico Conventional Lens Manufacturing 65,000 Owned
Southampton, United Kingdom Disposable Manufacturing/R&D 66,200 Leased
Southampton, United Kingdom Conventional Manufacturing 12,250 Leased
Farnham, United Kingdom RGP Manufacturing 5,000 Leased
Chandlers Ford, United Kingdom Conventional Manufacturing 24,500 Leased
Mississauga, Ontario Sales Office/Distribution 7,000 Leased
Bagnolet, France Sales Office/Distribution 6,997 Leased
Rome, Italy Sales Office/Distribution 7,750 Leased
Brooklyn, Australia Sales Office/Distribution 5,900 Leased
Tokyo, Japan Sales Office/Distribution 5,000 Leased
Madrid, Spain Sales Office * Leased
Reeuwijk, Holland Sales Office * Leased
Sao Paulo, Brazil Sales Office * Leased
Paris, France Sales Office * Leased
Munich, Germany Sales Office * Leased
</TABLE>
*Less than 5,000 square feet.
(1) This facility was closed in the fourth quarter of 1997.
Cidra, Puerto Rico. This 65,000 square foot facility was completed in 1991
and produces the Company's Durasoft and Optifit conventional clear and specialty
lenses.
Des Plaines, Illinois. This 340,000 square foot facility currently produces
all of the Company's FreshLook disposable lenses, and also houses its corporate
headquarters, research and development activities and other administrative
services.
15
<PAGE>
San Diego, California. This 136,700 square foot facility produces the
Company's CSI, Hydrocurve and Gentle Touch premium and toric lenses.
Additionally, the facility is used for U.S. distribution, customer service and
management information systems.
Southampton, United Kingdom. This 66,200 square foot facility was
substantially completed in 1996 and supports production of the Company's
Precision UV lenses.
Item 3. Legal Proceedings.
The Company is currently a party to various claims and legal actions which
arise in the ordinary course of business. The Company believes such claims and
legal actions, individually or in the aggregate, will not have a material
adverse effect on the business, financial condition or results of operations of
the Company. The Company carries insurance coverage in the types and amounts
that management considers reasonably adequate to cover the risks it faces in the
industry in which it competes. There can be no assurance, however, that such
insurance coverage will be adequate to cover all losses which the Company may
incur in future periods.
In connection with the Barnes-Hind Acquisition, Pilkington agreed, subject
to certain limitations, to retain responsibility for, and indemnify the Company
from and against, certain litigation and other claims. Notwithstanding these
contractual agreements, the Company could be pursued in the first instance by
third parties with respect to certain indemnified matters, subject to the
Company's right to seek indemnification from such seller. Management does not
currently believe that any such matter will have a material adverse effect on
the business or financial condition of the Company.
Item 4. Submission of Matters to a Vote of Security-Holders.
No matters were submitted to a vote of the Company's security-holders in
the fourth quarter of 1997.
Item 4A. Executive Officers of the Registrant.
<TABLE>
<CAPTION>
Name Age Position
---- --- --------
<S> <C> <C>
Stephen G. Pagliuca............. 43 Chairman of the Board
Kevin J. Ryan................... 57 President, Chief Executive Officer and
Director
Edward J. Kelley................ 50 Vice President, Finance, Chief Financial
Officer and Director
Raleigh S. Althisar, Jr......... 49 Vice President, Worldwide Manufacturing
Ronald J. Artale................ 47 Vice President and Controller
Lawrence L. Chapoy.............. 55 Vice President, Research & Development
William M. Flynn................ 39 Vice President, Pan Asia
Joseph F. Foos.................. 46 Vice President, Scientific Affairs
George H. McCrary............... 55 Vice President, Americas
Daniel M. Roussel............... 49 Vice President, Europe
Thomas F. Steiner............... 52 Vice President, Marketing
</TABLE>
Stephen G. Pagliuca has been Chairman of the Board of the Company since its
incorporation. Mr. Pagliuca has been a Managing Director of Bain Capital since
May 1993 and a general partner of Bain Venture Capital since 1989, where he
founded Information Partners. Prior to joining Bain Venture Capital, Mr.
Pagliuca was a partner at Bain & Company, where he provided strategic and
operational advice for clients in the healthcare and information industries. He
also worked as a senior accountant and international tax specialist for Peat
Marwick Mitchell & Company in the Netherlands. Mr. Pagliuca serves as Chairman
of the Board of Dade International Inc.
16
<PAGE>
and Physio-Control International Corporation. He also serves as a director of
several other companies including Coram Healthcare Corporation, Gartner Group,
Inc., Medical Specialties Group, Inc. and Physician Quality Care.
Kevin J. Ryan has served as President, Chief Executive Officer and a
Director of the Company since June 1995. From 1991 to 1995, Mr. Ryan was
President of BioSource Genetics Corporation. From 1987 to 1990, Mr. Ryan served
as President of the Barnes-Hind contact lens business; from 1983 to 1987, as
President of Revlon VisionCare (a division of Revlon, Inc.); and from 1978 to
1983, as President of Barnes-Hind (then a part of Revlon VisionCare).
Edward J. Kelley has served as Vice President, Finance, Chief Financial
Officer and a Director of the Company since June 1995. Prior to joining the
Company, Mr. Kelley served as the President, Asia Pacific and Latin America of
Barnes-Hind and its Chief Financial Officer. Prior to joining Barnes-Hind, Mr.
Kelley held positions of increasing responsibility with Simon & Schuster, Revlon
Health Care and Peat Marwick Mitchell & Company.
Raleigh S. Althisar, Jr. has served as Vice President, Worldwide
Manufacturing of the Company since October 1996. Prior to joining the Company,
Mr. Althisar served as Executive Vice President, Worldwide Manufacturing of
Barnes-Hind. Prior thereto, he held positions of increasing responsibility with
the Sola division of Barnes-Hind, Syntex Ophthalmics, Retail Optical Management
and Milton Roy Ophthalmics.
Ronald J. Artale has served as Vice President of the Company since February
1997 and Controller since March 1996. Prior to joining the Company, Mr. Artale
served as Corporate Vice President, Planning with Simon & Schuster. In addition,
Mr. Artale has held positions of increasing responsibility with Revlon
VisionCare, including Vice President, Finance for Barnes-Hind.
Lawrence L. Chapoy has served as Vice President, Research & Development of
the Company since 1993. Prior to joining the Company, Dr. Chapoy spent eight
years with Montedison Chemical Company as a Project Researcher and fifteen years
as a Chemical Engineering Professor at the Polytechnic University of Denmark. In
these positions, Dr. Chapoy conducted and managed research in a variety of
materials science related areas. Dr. Chapoy holds more than 25 patents, has
authored more than 75 publications and presented over 100 lectures during the
course of his career.
William M. Flynn has served as the Vice President, Pan Asia of the Company
since 1994. Prior to being named to his current position, Mr. Flynn served as
International Finance Manager for two years and in the other positions in the
Finance Department of Schering-Plough Corporation for two years. In addition,
Mr. Flynn held a variety of finance positions with Prudential Insurance Company
of America and RCA Records.
Joseph F. Foos has served as Vice President, Scientific Affairs of the
Company since 1994. Mr. Foos joined Wesley Jessen in 1987 and has served as
Manager, Quality for two years, Project Manager for Research and Development
Pilot Manufacturing and various other positions of increasing responsibility.
George H. McCrary has served as Vice President, Americas of the Company
since 1996. Prior to joining the Company, Mr. McCrary held the position of
Senior Vice President of Sales, Marketing and Distribution for Foster Grant
Corporation and prior to that, Vice President Sales and Marketing, Consumer
Products Division for Revlon VisionCare. Before joining Revlon VisionCare, he
held sales and marketing positions of increasing responsibility with the Warner-
Lambert Company.
Daniel M. Roussel has served as Vice President, Europe for Wesley Jessen
since 1995. Mr. Roussel opened the Company's French subsidiary and served for
three years as General Manager Wesley Jessen, France. Previously, Mr. Roussel
held positions in marketing and sales with Schering-Plough in Hong Kong, Japan,
and Portugal. Mr. Roussel also worked as Regional Director, Asia Pacific, for
Goupit Labs based in Hong Kong.
17
<PAGE>
Thomas F. Steiner has served as Vice President, Marketing of the Company
since 1996. Mr. Steiner has served in various marketing-related positions since
joining the Company in 1982. Prior to joining the Company, Mr. Steiner worked at
Sara Lee Corporation for seven years as Group Product Manager and Project
Research Manager. Mr. Steiner also worked at J. Walter Thompson Company as
Associate Research Director.
There are no family relationships between any of the executive officers of
the Company.
PART II
Item 5. Market for the Registrant's Common Equity and Related Stockholder
Matters.
Market Information
The Common Stock is traded on the Nasdaq National Market ("Nasdaq") under
the symbol "WJCO." The Common Stock commences trading on February 13, 1997. The
following table sets forth on a per share basis, the high and low bid sale
prices per share for the Common Stock as reported by the Nasdaq for the period
indicated:
<TABLE>
<CAPTION>
High Low
---- ---
1997:
<S> <C> <C>
First Quarter (from February 13, 1997)............. $16.75 $14.63
Second Quarter..................................... 25.88 13.00
Third Quarter...................................... 31.00 22.50
Fourth Quarter..................................... 39.00 26.25
1998:
First Quarter (through March 24, 1998)............. 40.25 31.38
</TABLE>
Holders
As of the close of business on March 24, 1998, there were approximately
2,698 holders of record of Common Stock. The Company believes that it has a
significantly larger number of beneficial holders of Common Stock. A recent
reported last sale price of the Common Stock on the Nasdaq is set forth on the
cover page of this report.
Dividends
Since its incorporation in 1995, the Company has not declared or paid any
cash or other dividends on its Common Stock and does not expect to pay dividends
for the forseeable future. Instead, the Company currently intends to retain
earnings to support its growth strategy and reduce indebtedness. As a holding
company, the ability of the Company to pay dividends in the future is dependent
upon the receipt of dividends or other payments from its principal operating
subsidiary. The Company's Bank Credit Agreement permits the payment of dividends
of up to $3.0 million annually plus certain excess cash available at the time of
payment, if any. Any future determination to pay dividends will be at the
discretion of the Company's Board of Directors and will depend upon, among other
factors, the Company's results of operations, financial condition, capital
requirements and contractual restrictions.
Recent Sales of Unregistered Securities
No securities of the Company that were not registered under the Securities
Act have been issued or sold by the Company within the period covered by this
report.
18
<PAGE>
Item 6. Selected Financial Data.
The selected financial data presented below has been derived from the
consolidated financial statements of the Company. The financial statements for
each of the years in the five year period ended December 31, 1997 have been
audited by Price Waterhouse LLP, independent accountants. This selected
financial data should be read in conjunction with "Management's Discussion and
Analysis of Results of Operations and Financial Condition" and the Company's
Consolidated Financial Statements and Notes.
<TABLE>
<CAPTION>
Predecessor Company
------------------------------------ ------------------------------------
January 1, June 29,
Year Ended through through Year Ended
----------------------- June 28, December 31, --------------------
1993 1994 1995 1995 1996 1997
---- ---- ---- ---- ---- ----
<S> <C> <C> <C> <C> <C> <C>
Statements of Income
Net sales $103,386 $109,640 $ 51,019 $ 54,315 $156,752 $282,178
Income (loss) before income
taxes and extraordinary loss (35,546) (57,421) (22,544) (33,737) (4,108) 12,388
Net income (loss) before
extraordinary loss (18,332) (30,486) (13,143) (19,715) (1,071) 8,200
Extraordinary loss, net of income
tax benefit - - - - (1,671) (4,902)
Net income (loss) (18,332) (30,486) (13,143) (19,175) (2,742) 3,298
Income (loss) per common share:
Basic
Net income (loss) before
extraordinary loss $ (1.37) $ (0.07) $ 0.49
Extraordinary loss, net of income
tax benefit $ - $ (0.12) $ (0.29)
Net income (loss) $ (1.37) $ (0.19) $ 0.20
Diluted
Net income (loss) before
extraordinary loss $ (1.37) $ (0.07) $ 0.45
Extraordinary loss, net of income $ - $ (0.12) $ (0.27)
tax benefit
Net income (loss) $ (1.37) $ (0.19) $ 0.18
Balance Sheets:
Working capital $ 42,538 $ 30,940 $ 30,262 $ 77,747 $ 65,835
Total assets 214,747 191,429 67,330 180,600 173,076
Total debt - - 42,000 102,975 57,000
Stockholders' equity (deficit) 196,243 173,409 (12,190) (13,292) 36,846
</TABLE>
Item 7. Management's Discussion and Analysis of Financial Condition and
Results of Operations.
Overview
Wesley Jessen is the leading worldwide developer, manufacturer and marketer
of specialty soft contact lenses, based on its share of the specialty lens
market. The Company's products include cosmetic lenses, which change or enhance
the wearer's eye color appearance; toric lenses, which correct vision for people
with astigmatism; and premium lenses, which offer value-added features such as
improved comfort for dry eyes and protection from UV light. Founded in 1946 by
pioneers in the contact lens industry, the Company has a long-standing
reputation for innovation and new product introductions. Wesley Jessen develops
technology, manufacturing processes and products through a combination of its
in-house staff of more than 50 engineers and scientists and Company-sponsored
research by third-party experts. The Company markets and sells its products to
consumers through the
19
<PAGE>
second largest advertising campaign in the industry and to eyecare practitioners
through its 196-person salesforce and network of 76 independent distributors,
which together sell the Company's products in more than 75 countries.
Wesley Jessen Acquisition
On June 28, 1995, Bain Capital, together with new and certain then-existing
members of management, acquired the Wesley Jessen contact lens business (the
"Predecessor") from Schering-Plough Corporation (the "Wesley Jessen
Acquisition"). The cash purchase price in the Wesley Jessen Acquisition of $47.0
million (plus fees and expenses of $3.5 million) was funded with $7.5 million of
equity and $43.0 million of borrowings under a bank credit agreement. The
aggregate purchase price in the Wesley Jessen Acquisition, including assumed
liabilities, was $76.6 million. The Wesley Jessen Acquisition was accounted for
under the purchase method of accounting and included an increase in the book
value of the inventory which was charged to cost of goods sold in subsequent
periods. After the Wesley Jessen Acquisition, the Company's new management team
pursued an aggressive strategy of cost savings and revenue enhancement to
improve the Company's results of operations. During this period, management: (i)
redefined the Company's disposable and conventional lens marketing strategy by
repricing and repackaging the Company's products to be more competitive with
industry standards; (ii) launched a national consumer advertising campaign
featuring Christy Turlington; (iii) expanded its product offerings in its
FreshLook line of disposable colored contact lenses; (iv) heightened its sales
and marketing focus on serving the needs of eyecare practitioners; and (v)
achieved substantial cost savings through personnel reductions, decreased
overall marketing and advertising expenses, consolidation of facilities and
increased operating efficiencies. As a result of management's efforts, the
Company's profitability and results of operations have improved significantly
following the Wesley Jessen Acquisition.
As a result of the Wesley Jessen Acquisition, the Company recognized a
significant non-cash increase in cost of goods sold of $33.9 million in 1995 and
$6.6 million in 1996 related to the amortization of Wesley Jessen purchased
inventory step-up to fair value at the acquisition date. Following the
acquisition, the Company realized cost savings of $4.9 million in 1995 related
primarily to the consolidation of duplicative facilities including corporate
offices and marketing support facilities, as well as a reduction in the actual
number of corporate level employees and related expenses. Adjustments for these
non-recurring charges and cost savings have been reflected in the Company's
unaudited Pro Forma Statement of Operations Data. See "Results of Operations."
While the Company believes that these expenses will not recur, there can be no
assurance that the Company will be able to achieve such cost savings in future
periods.
Barnes-Hind Acquisition
On October 2, 1996, the Company acquired substantially all the assets and
assumed certain liabilities of the Pilkington Barnes-Hind Group from Pilkington
plc (the "Barnes-Hind Acquisition"). The purchase price in the Barnes-Hind
Acquisition of approximately $62.4 million (plus related acquisition and
financing fees of $10.7 million) was funded with approximately $68.1 million of
borrowings under the $140.0 million credit agreement and a $5.0 million seller
note (the "Pilkington Note"). Concurrently, the Company borrowed an additional
$28.5 million to repay its then outstanding term loans and to fund ongoing
working capital needs.
In connection with the Barnes-Hind Acquisition, the Company entered into a
voluntary consent order with the Federal Trade Commission which provided, among
other things, that the Company divest Barnes-Hind's U.S. Natural Touch product
line. On March 17, 1997, the Company completed the sale of the product line for
which it received aggregate consideration of $7.5 million, consisting of $3.0
million in cash and a four-year $4.5 million promissory note which accrues
interest at a compound rate of 12% per annum, 8% of which is payable currently
and 4% of which is payable-in-kind. On July 31, 1997, the purchaser made a
voluntary prepayment of $3.0 million on the promissory note. As part of the
agreement, the Company entered into a supply agreement pursuant to which the
Company will supply the purchaser with Natural Touch lenses for sale in the
United States.
20
<PAGE>
In September, 1997, the Company negotiated a purchase price reduction of
$1.6 million with Pilkington plc based upon specified net current asset measures
as of the closing date of the acquisition. As a result, the purchase price of
Barnes-Hind, after taking into consideration additional acquisition related fees
and expenses, decreased by $0.1 million. Additionally, certain pension
valuations associated with the Barnes-Hind employees were completed in the third
quarter of 1997. Management also revised the operational details and related
cost estimates of its plans to integrate the Barnes-Hind operations. These
changes in estimates resulted in recognition of negative goodwill of $4.0
million, which will be amortized to income through June, 2010.
In connection with the Barnes-Hind Acquisition, the Company identified
significant operating synergies and substantial cost saving opportunities. The
Company has completed the majority of its initial cost reduction measures which
are expected to improve the Company's operating results. The Company believes
that additional cost savings are available through consolidation of facilities
and operating leverage. However, there can be no assurance that the Company will
be able to achieve such cost savings in future periods.
As a result of the Barnes-Hind Acquisition, the Company incurred
significant non-recurring charges as follows: (i) a non-cash increase in cost of
goods sold of $14.1 million in 1996 and $22.7 million in 1997 related to the
amortization of the Barnes-Hind purchased inventory step-up to fair value at the
acquisition date; and (ii) extraordinary debt extinguishment costs of $2.8
million ($1.7 million, net of income tax benefit) in 1996 related to the write-
off of capitalized financing fees incurred in connection with the refinancing of
the Company's then- existing credit agreement. Adjustments for these non-
recurring charges and expected cost savings related to the reduction of certain
operating expenses including the consolidation of corporate offices, a reduction
in the number of corporate level employees and related expenses, and the
curtailment of certain manufacturing activities, as well as the adjustments for
the Wesley Jessen Acquisition, have been reflected in the Company's unaudited
Pro Forma Statement of Operations Data. See "Results of Operations."
The IPO and the Offering
In February, 1997, the Company consummated an initial public offering (the
"IPO") of 2.8 million shares of Common Stock at $15.00 per share. A secondary
public offering (the "Offering") of 4.3 million shares of Common Stock at $23.50
per share was completed in August, 1997, of which 3.8 million shares were sold
by certain selling stockholders and 0.5 million shares were sold by the Company.
In connection with the IPO, the Company incurred a non-recurring charge for
extraordinary debt extinguishment costs of $7.4 million ($4.9 million, net of
income tax benefit) related to the write-off of capitalized financing fees
incurred in connection with the Barnes-Hind Acquisition financing. Additionally,
the Company incurred and capitalized financing fees of $2.5 million, which are
being amortized over 60 months.
In September, 1997, in connection with the Offering, the Company entered
into the Amended Bank Credit Agreement which increased the total borrowing
availability thereunder to $135.0 million, converted all remaining term loan
borrowings into revolving loans, and reduced the interest rate thereunder. The
Company incurred an additional $0.6 million of fees and expenses associated with
the Amended Bank Credit Agreement. These costs have been capitalized and are
being amortized through September 2002.
Interest expense reductions as if the IPO had occurred on January 1, 1995
are reflected in the Company's unaudited Pro Forma Statement of Operations Data.
See "Results of Operations." However, there can be no assurance that the
Company's interest expense will not increase in future periods either as a
result of increased borrowings or higher interest rates.
21
<PAGE>
Results of Operations
The Wesley Jessen and Barnes-Hind Acquisitions occurred on June 29, 1995
and October 2, 1996, respectively. Because of the revaluation of assets and
liabilities and the related impact on cost of sales and expenses and the several
cost-reduction and operating improvements undertaken in connection with such
Acquisitions, the financial statements of the Company for the years ended
December 31, 1995, 1996 and 1997 are not comparable. In addition, the Company
completed its IPO in February, 1997, which had a significant impact on the
Company's on-going interest expense. To improve the comparability of the
Company's last three fiscal years, and to assist the reader in better
understanding the changes in the Company's operations over such periods, the
Company has set forth below certain pro forma operating results. Such pro forma
statement of operations data gives effect to the Wesley Jessen and the Barnes-
Hind Acquisitions and the IPO as if such transactions occurred on January 1,
1995. The pro forma adjustments for each period presented are set forth in the
notes to the table. The pro forma information included herein is presented for
informational purposes only and should not be viewed as a substitute for the
Company's results of operations calculated in accordance with generally accepted
accounting principles. In addition, the following pro forma information does not
purport to represent the results of operations or financial position of the
Company had such transactions in fact occurred on such date, nor do they purport
to be indicative of the financial position or results of operations as of any
future date or any future periods. The following pro forma information should
be read in conjunction with the Consolidated Financial Statements of the Company
included herein.
Unaudited Pro Forma Statement of Operations Data
(in thousands)
<TABLE>
<CAPTION>
Year Ended December 31,
---------------------------------------
1995(a) 1996(b) 1997(c)
-------- -------- --------
<S> <C> <C> <C>
Statement of Operations Data:
Net sales.................................... $230,997 $249,999 $282,178
Operating costs and expenses:
Cost of goods sold....................... 91,681 86,568 92,780
Marketing and administrative............. 120,876 127,030 136,565
Research and development................. 13,670 12,050 11,997
Amortization of intangible assets
(negative goodwill)..................... (784) (784) (862)
-------- -------- --------
Income from operations................... 5,554 25,135 41,698
Other (income) expense:
Interest expense, net.................... 5,809 5,809 5,148
Other income, net........................ (1,360) (3,051) -
-------- -------- --------
Income before income taxes................... 1,105 22,377 36,550
-------- -------- --------
Income tax expense........................... (376) (7,608) (12,244)
-------- -------- --------
Net income................................... $ 729 $ 14,769 $ 24,306
======== ======== ========
</TABLE>
(a) The pro forma results comprise the Wesley Jessen operations and the Barnes-
Hind operations and include adjustments for (i) a net reduction in interest
expense of $332 associated with the financing of the Wesley Jessen
Acquisition and Barnes-Hind Acquisition and the refinancing in connection
with the IPO; (ii) net cost savings of $20,345 relating to the reduction of
certain operating expenses including the consolidation of corporate
offices, a reduction in the number of corporate-level employees and related
expenses, consolidation of marketing support facilities, rationalization of
the international sales and marketing functions and curtailment of certain
manufacturing facilities; (iii) elimination of the inventory step-up
amortization of $33,929; (iv) a net reduction in depreciation and
amortization expense of $7,472 as a result of the Company's application of
purchase accounting; (v) the divestiture of the U.S. Natural Touch product
line of $1,817; (vi) the elimination of Corporate financing fees charged by
Schering-Plough to the Predecessor of $3,511; and (vii) the adjusted income
tax expense resulting from the preceding adjustments at an effective income
tax rate of 34%.
(b) The pro forma results comprise the Wesley Jessen operations and the Barnes-
Hind operations and include adjustments for (i) a net increase in interest
expense associated with the financing of the Barnes-Hind Acquisition
22
<PAGE>
and the refinancing in connection with the IPO of $386; (ii) net cost
savings of $20,712 relating to the reduction of certain operating expenses
including the consolidation of corporate offices, a reduction in the number
of corporate-level employees and related expenses, and the curtailment of
certain manufacturing activities; (iii) elimination of inventory step-up
amortization of $20,706; (iv) a net reduction in depreciation and
amortization expense of $2,876 as a result of the Company's application of
purchase accounting; (v) the divestiture of the U.S. Natural Touch product
line of $1,039; (vi) the elimination of the extraordinary write-off of
capitalized financing fees of $1,671; and (vii) the adjusted income tax
expense resulting from the preceding adjustments at an effective income tax
rate of 34%.
(c) The pro forma results include adjustments for (i) interest expense of $411
associated with the refinancing in connection with the IPO; (ii) cost
savings of $1,085 relating to the reduction of certain operating expenses
including the consolidation of corporate offices, a reduction in the number
of corporate-level employees and related expenses, and the curtailment of
certain manufacturing activities; (iii) elimination of inventory step-up
amortization of $22,666; (iv) the elimination of the extraordinary write-
off of capitalized financing fees of $4,902; and (vii) the adjusted income
tax expense resulting from the preceding adjustments at an effective income
tax rate of 33.5%.
23
<PAGE>
Pro Forma Year Ended December 31, 1997 (Unaudited) Compared to Pro Forma Year
Ended December 31, 1996 (Unaudited)
The following discussion compares the Company's pro forma results of
operations for the year ended December 31, 1997 to the pro forma results of
operations for the year ended December 31, 1996.
Net sales for the year ended December 31, 1997 increased $32.2 million, or
12.9%, to $282.2 million from $250.0 million for the year ended December 31,
1996. This increase resulted primarily from 38.1% growth in sales of the
Company's disposable and planned replacement contact lenses, from $71.0 million
to $98.0 million, along with a moderate increase in the conventional lens
product lines of 3.1%. Sales of disposable and planned replacement contact
lenses grew 51.4% in the U.S. and 27.6% internationally. Total sales in the
United States grew 17.4%, while sales in the rest of the world grew 7.8% for the
year. The sales returns and allowances reserve decreased slightly from $10.6
million at December 31, 1996 to $10.4 million at December 31, 1997. This is a
result of lower actual sales returns and allowances trends which the Company
experienced throughout the year.
Gross profit for the year ended December 31, 1997 increased $26.0 million,
or 15.9%, to $189.4 million from $163.4 million in the comparable 1996 period.
Gross profit margin improved 1.7% to 67.1% in 1997, reflecting the higher
margins realized on the Company's disposable and planned replacement lenses due
to higher production volumes, as well as cost savings from improved plant
utilization and other operating efficiencies.
Marketing and administrative expenses increased by $9.5 million, or 7.5%,
to $136.6 million in 1997 from $127.0 million in 1996, largely due to higher
promotional spending for all product lines, particularly the former Barnes-Hind
conventional lens products, along with higher performance related compensation
expenses. As a percentage of net sales, though, marketing and administrative
expenses decreased to 48.4% in 1997 from 50.8% in 1996.
Income from operations of $41.7 million for the year ended December 31,
1997 increased 65.9% from $25.1 million for the year ended December 31, 1996 due
to the overall increase in sales volume along with improvement in the Company's
gross margin offset slightly by the increase in marketing and administrative
expenses.
Interest expense, net decreased 11.4% to $5.1 million in 1997 from $5.8
million in 1996 due to the paydown of debt with proceeds from the Offering as
well as interest income earned on the promissory note receivable related to the
sale of the Company's Natural Touch product line.
Other income for the year ended December 31, 1996 includes $3.7 million of
non-recurring licensing fee income. There was no such income in the comparable
1997 period.
Net income for the year ended December 31, 1997 increased $9.5 million to
$24.3 million from $14.8 million for the year ended December 31, 1996. Excluding
the 1996 licensing fee income, net income increased $12.0 million. This resulted
from higher sales volume and improvement in the Company's gross margins,
partially offset by increased spending in marketing and administrative expenses.
Pro Forma Year Ended December 31, 1996 (Unaudited) Compared to Pro Forma Year
Ended December 31, 1995 (Unaudited)
The following discussion compares the Company's pro forma results of
operations for the year ended December 31, 1996 to the pro forma results of
operations for the year ended December 31, 1995.
Net sales for the year ended December 31, 1996 increased $19.0 million, or
8.2%, to $250.0 million from $231.0 million for the year ended December 31,
1995. This increase resulted primarily from the following: (i) the Company's
redefined marketing strategy of repricing and repackaging disposable and
conventional lenses to be more competitive; (ii) the expansion of product
offerings in the FreshLook line of disposable colored contact lenses; and (iii)
unit volume growth, driven by new marketing programs and the continued
penetration of the Company's cosmetic lenses. Following the Wesley Jessen
Acquisition, the Company adopted more stringent return and exchange policies,
which lowered product returns and allowances and resulted in generally lower
reserve requirements. The sales returns and allowances reserve increased from
$7.2 million at December 31, 1995 to $10.6 million at December 31, 1996. This is
a result of the addition of Barnes-Hind sales in the fourth quarter of 1996, the
conformity of Barnes-Hind reserve methodology to that of the Company's and the
overall increase in sales volume.
24
<PAGE>
Gross profit for the year ended December 31, 1996 increased $24.1 million,
or 17.3%, to $163.4 million from $139.3 million in the comparable 1995 period.
Gross profit margin increased to 65.4% for the year ended December 31, 1996 from
60.3% in the comparable period. This improvement reflects the cost savings that
resulted from improved plant utilization, personnel reductions and other
operating efficiencies. Gross profit for the year ended December 31, 1995 was
negatively impacted by a write-off of $2.2 million related to conventional lens
inventory produced prior to the Wesley Jessen Acquisition that did not meet new
management's higher standards for customer satisfaction. Excluding this effect,
gross profit margin for the year ended December 31, 1995 would have been 61.3%.
Marketing and administrative expenses for the year ended December 31, 1996
increased by $6.2 million, or 5.1%, to $127.0 million from $120.9 million for
the year ended December 31, 1995. However, as a percentage of sales, marketing
and administrative expenses decreased to 50.8% in 1996 from 52.3% in the 1995
period. These increased marketing and administrative expenses are largely due to
higher promotional spending and an increase in performance related compensation
expenses.
Research and development expenses for the year ended December 31, 1996
decreased by $1.6 million, or 11.9% to $12.1 million from $13.7 million for the
year ended December 31, 1995. As a percentage of net sales, research and
development expenses for the year ended December 31, 1996 decreased to 4.8% from
5.9% in the prior year. This decrease is due to the successful completion of
1995 manufacturing development projects which became operational in 1996.
Income from operations for the year ended December 31, 1996 increased by
$19.6 million to income of $25.1 million from $5.6 million for the year ended
December 31, 1995. This increase resulted from the improvement in the Company's
gross margin resulting from improved plant utilization due to unit volume growth
and overall cost reductions, partially offset by increased promotional spending
and higher performance related compensation expenses.
Other income for the year ended December 31, 1996 increased by $1.7 million
to $3.1 million in 1996 from $1.4 million in 1995. This increase is due
primarily to an increase of $2.7 million in licensing fee income from 1995 to
1996, partially offset by unfavorable foreign exchange variances recognized in
1996.
Net income for the year ended December 31, 1996 increased by $14.0 million
to $14.8 million from $0.7 million for the year ended December 31, 1995. This
increase is due to improvement in the Company's gross margin offset by higher
marketing and administrative expenses.
Liquidity and Capital Resources
The Company generates significant cash from operations and has adequate
borrowing capacity under its revolving credit facility to meet its operating and
discretionary spending requirements. Net cash provided by operating activities
for the period from June 29, 1995 through December 31, 1995 totaled
approximately $4.0 million. For the year ended December 31, 1996, the Company
generated approximately $19.2 million in cash from operating activities,
primarily as a result of increases in profitability (giving effect to the
inventory step-up amortization), a decrease in accounts receivable and increases
in income taxes payable and accrued liabilities offset by a decrease in accounts
payable. For the year ended December 31, 1997, the Company generated
approximately $6.9 million in cash from operating activities, primarily as a
result of continued increases in profitability (giving effect to the inventory
step-up amortization and the extraordinary loss), partially offset by working
capital requirements and payments under the plan to integrate the Barnes-Hind
operations. Since December 31, 1996, the Company has reduced its long term debt
by $46.0 million, entirely due to proceeds received from the IPO and the
Offering.
During the period from June 29, 1995 to December 31, 1995, and for the
years ended December 31, 1996 and 1997, the Company made capital expenditures of
approximately $0.9 million, $6.6 million and $16.3 million, respectively. The
majority of these capital expenditures were for facility and equipment
improvement, information technology enhancements, and site consolidations.
During 1995 Barnes-Hind incurred significant capital expenditures for
improvements in information technology and manufacturing efficiencies, including
the partial automation of the United Kingdom disposable lens manufacturing
lines. The Company anticipates future capital expeditures will be incurred to
further consolidate locations, enhance the Company's management information
systems, and to expand production capacity. The Company expects to fund these
capital expenditures primarily from cash generated from operating activities and
borrowings under its revolving credit facility.
25
<PAGE>
In connection with the Wesley Jessen Acquisition, the Company initiated a
series of restructuring activities as part of its cost rationalization program.
As part of such acquisition, Schering-Plough agreed to incur significant one-
time expenses associated with the elimination of approximately 430 positions. In
addition, the Company has expended $5.5 million in cash from June 29, 1995
through December 31, 1997 to close facilities. As a result of the Barnes-Hind
Acquisition, the Company expects to incur integration costs of approximately
$20.4 million, principally for severance costs and lease expenses on vacated
premises. Management expects that this restructuring will be substantially
completed by April, 1999. As of December 31, 1997, the Company has paid $9.2
million of these integration costs.
As a result of the Acquisitions, the Company's borrowings under its credit
facilities increased significantly as did its liquidity requirements. As of
December 31, 1997, the Company had approximately $78.0 million in borrowing
availability under the revolving credit facility portion of the Amended Bank
Credit Agreement. The Amended Bank Credit Agreement imposes certain restrictions
on the Company, including restrictions on its ability to incur indebtedness,
declare dividends or other distributions, make investments and capital
expenditures, grant liens, sell its assets and engage in certain other
activities. In addition, the indebtedness of the Company under the Amended Bank
Credit Agreement is secured by substantially all of the assets of the Company,
including the Company's real and personal property, inventory, accounts
receivable, intellectual property and other tangible assets.
Management believes that, based on current levels of operations and
anticipated internal growth, the Company's cash flow from operations, together
with other available sources of funds including borrowings under the Amended
Bank Credit Agreement and available cash on hand at December 31, 1997, of $4.6
million, will be adequate over the next twelve months to make required payments
of principal and interest on the Company's indebtedness, to fund anticipated
capital expenditures and working capital requirements, including the
aforementioned restructuring and integration costs, and to enable the Company
and its subsidiaries to comply with the terms of their debt agreements. However,
actual capital requirements may change, particularly as a result of any
acquisitions the Company may pursue. The ability of the Company to meet its debt
service obligations and reduce its total debt will be dependent, however, upon
the future performance of the Company and its subsidiaries which, in turn, will
be subject to general economic conditions and to financial, business and other
factors, including factors beyond the Company's control. A portion of the
consolidated debt of the Company bears interest at floating rates; therefore,
the Company's financial condition is and will continue to be affected by changes
in prevailing interest rates. In December, 1996, the Company purchased an
interest rate cap on $35.0 million of notional principal amount at a fixed rate
of 8.5%, which expires on December 31, 1999. The cap is intended to provide
partial protection from potential exposure relating to the Company's variable
rate debt instruments.
Approximately 43% of the Company's net sales for the year ended December
31, 1997 were to international customers and the Company expects that sales to
international customers will continue to represent a material portion of its net
sales. Historically, fluctuations in foreign currency exchange rates have had
only a minor impact on the Company's results of operations and the Company does
not expect such fluctuations to be material in the foreseeable future.
Seasonality
Historically, the Company has experienced limited seasonality, with
slightly greater revenues in the quarters ended June and September and slightly
lower revenues in the quarters ended March and December. The following table
sets forth the unaudited operating results of the Company for the last eight
fiscal quarters, excluding the impact of the inventory step-up.
<TABLE>
<CAPTION>
Quarter Ended
- - ------------------------------------------------------------------------------------------------------------------------------
March June September December March June September December
31, 1996 29, 1996 28, 1996 31, 1996 29, 1997 28, 1997 27, 1997 31, 1997
- - ------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Statement of Operations Data:
Net sales.............................. $30,147 $32,250 $33,651 $60,704 $64,071 $72,083 $75,235 $70,789
Gross profit........................... 21,686 22,277 25,614 44,023 42,201 47,137 51,344 48,716
Income from operations................. 4,088 5,298 5,979 3,567 6,120 10,284 11,989 12,220
Other Data:
Amortization of negative goodwill...... $ (196) $ (196) $ (196) $ (196) $ (196) $ (196) $ (196) $ (274)
Depreciation........................... 8 37 114 303 122 231 231 317
Inventory step-up amortization......... 5,953 673 - 14,080 13,092 9,574 - -
</TABLE>
26
<PAGE>
Inflation
Management believes that inflation has not had a material impact on results
of operations for the Company or the Predecessor during the three years ended
December 31, 1997.
Recently Issued Accounting Pronouncements
Statement of Financial Accounting Standards ("SFAS") No. 130, "Reporting
Comprehensive Income," issued in June, 1997, will require the Company to
disclose, in financial statement format, all non-owner changes in equity. Such
changes include, for example, cumulative foreign currency translation
adjustments, certain minimum pension liabilities and unrealized gains and losses
on available-for-sale securities. This Statement is effective for fiscal years
beginning after December 15, 1997 and requires presentation of prior period
financial statements for comparability purposes. The Company will adopt this
Statement in its financial statements for the year ending December 31, 1998.
SFAS No. 131, "Disclosures about Segments of an Enterprise and Related
Information," issued in June, 1997, establishes standards for reporting
information about operating segments in annual financial statements and interim
financial reports. It also establishes standards for related disclosures about
products and services, geographic areas and major customers. Operating segments
are components of an enterprise about which separate financial information is
available that is evaluated regularly by the chief operating decision maker in
deciding how to allocate resources and in assessing performance. Generally,
financial information is required to be reported on the basis that is used
internally for evaluating segment performance and deciding how to allocate
resources to segments. The Company is currently evaluating the potential impact
of the Statement, which it will adopt in its financial statements for the year
ending December 31, 1998.
SFAS No. 132, "Employers' Disclosures about Pensions and Other
Postretirement Benefits," issued in February, 1998, standardizes the disclosure
requirements for pensions and other postretirement benefits. Amending SFAS 87,
"Employers' Accounting for Pensions," SFAS 88, "Employers' Accounting for
Settlements and Curtailments of Defined Benefit Pension Plans and for
Termination Benefits," and SFAS 106, "Employers' Accounting for Postretirement
Benefits Other Than Pensions," it requires additional disclosure of changes in
benefit obligations and fair values of plan assets. This Statement is effective
for fiscal years beginning after December 15, 1997 and requires presentation of
prior period information for comparability purposes. The Company expects to
adopt this Statement in its financial statements for the year ending December
31, 1998.
Other Matters
The Company currently is working to resolve the potential impact of the
year 2000 on the processing of date-sensitive information by the Company's
management information systems and other computerized systems. The year 2000
problem is the result of computer programs being written using two digits,
rather than four, to define the applicable year. Any of the Company's programs
that have time-sensitive software may recognize a date using "00" as the year
1900 rather than the year 2000, which could result in miscalculations or system
failures. Based on preliminary information, costs of addressing potential
problems are not currently expected to have a material adverse effect on the
Company's financial position, results of operations or cash flows in future
periods. However, if the Company, its customers or vendors are unable to resolve
such processing issues in a timely manner, it could result in a material
financial risk. Accordingly, the Company plans to devote the necessary resources
to resolve all significant year 2000 issues in a timely manner.
Forward-Looking Statements
The Management's Discussion and Analysis of Financial Condition and Results
of Operations ("MD&A") contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended (the "Securities Act").
Such forward-looking statements are based on the beliefs of the Company's
management as well as on assumptions made by and information currently available
to the Company at the time such statements were made. When used in this MD&A,
the words "anticipate," "believe," "estimate," "expect," "intends," and similar
expressions, as they relate to the Company are intended to identify forward-
looking statements, which include statements relating to, among other things,
(i) the ability of the Company to continue to compete successfully in the
contact lens market; (ii) the anticipated benefits from new product
introductions; (iii) the completion of the integration of Barnes-Hind with the
Company; (iv) the strategic benefits of the Barnes-Hind Acquisition; (v) the
continued effectiveness of the Company's
27
<PAGE>
sales and marketing strategy; and (vi) the ability of the Company to continue to
successfully develop and launch new products. Actual results could differ
materially from those projected in the forward-looking statements as a result of
the matters discussed herein and certain economic and business factors, some of
which may be beyond the control of the Company.
Item 7A. Quantitative and Qualitative Disclosure About Market Risk.
The Company is a non-bank and non-thrift registrant with a market
capitalization on January 28, 1997 of less than $2.5 billion. As a result, Item
305 disclosure is not required in filings with the Commission that include
financial statements for years ending before June 15, 1998.
Item 8. Financial Statements and Supplementary Data.
The information required by Item 8 is set forth on pages F-1 through F-31
of this Form 10-K. The supplementary financial information required by Item 302
of Regulation S-K is set forth on F- of this Form 10-K.
Item 9. Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure.
None.
PART III
Item 10. Directors and Executive Officers of the Registrant.
Information with respect to Directors of the Company is set forth in the
Proxy Statement under the heading "Election of Directors," which information is
incorporated herein by reference. Information regarding the executive officers
of the Company is included as Item 4A of Part I of the Form 10-K as permitted by
Instruction 3 to Item 401(b) of Regulation S-K. Information required by Item 405
of Regulation S-K is set forth in the Proxy Statement under the heading "Section
16(a) Beneficial Ownership Reporting Compliance," which information is
incorporated herein by reference.
Item 11. Executive Compensation.
Information with respect to executive compensation is set forth in the
Proxy Statement under the heading "Compensation of Executive Officers," which
information is incorporated herein by reference (except for the Compensation
Committee Report on Executive Compensation and the Performance Graph).
Item 12. Security Ownership of Certain Beneficial Owners and Management.
Information with respect to security ownership of certain beneficial owners
and management is set forth in the Proxy Statement under the heading "Beneficial
Ownership of Common Stock," which information is incorporated herein by
reference.
Item 13. Certain Relationships and Related Transactions.
Information with respect to certain relationships and related transactions
is set forth in the Proxy Statements under the headings "Election of Directors--
Compensation Committee Interlocks and Insider Participation" and "Election of
Directors--Certain Relationships and Related Transactions," which information
is incorporated herein by reference.
PART IV
Item 14. Exhibits, Financial Statement Schedules and Reports on Form 8-K.
(a) The following documents are filed as part of this report:
28
<PAGE>
1. Financial Statements. The following consolidated financial
statements of the Predecessor and the Company and the reports of
the independent auditors thereon, are included in this Form 10-K
on pages 30 through 57:
Report of Independent Accountants--Company
Report of Independent Accountants--Predecessor
Consolidated Balance Sheets of the Company at December 31, 1996
and 1997
Consolidated Statements of Operations of the Predecessor for the
period January 1, 1995 through June 28, 1995 and of the Company
for the period June 29, 1995 through December 31, 1995 and for
the years ended December 31, 1996 and 1997
Consolidated Statements of Cash Flows of the Predecessor for the
period January 1, 1995 through June 28, 1995 and of the Company
for the period June 29, 1995 through December 31, 1995 and for
the years ended December 31, 1996 and 1997
Consolidated Statements of Changes in Stockholders' Equity of the
Company for the period June 29, 1995 through December 31, 1995
and for the years ended December 31, 1996 and 1997
Notes to Consolidated Financial Statements
2. Supplemental Unaudited Financial Data. Quarterly Financial Data
3. Financial Statement Schedules. The following financial statement
schedule of the Predecessor for the period from January 1, 1995
through June 28, 1995 and of the Company for the period from June
29, 1995 to December 31, 1995 and for the years ended December 31,
1996 and 1997 is included in the Form 10-K on page 59.
Schedule No. Description Page No.
------------ ----------- --------
Schedule II Valuation and Qualifying Accounts 59
All other financial statement schedules have been omitted because they
are inapplicable or the required information is included or
incorporated by reference elsewhere herein.
Report of Independent Accountants on Financial
Statement Schedule
4. Exhibits. The Company will furnish to any eligible stockholder,
upon written request of such stockholder, a copy of any exhibit
listed below upon the payment of a reasonable fee equal to the
Company's expenses in furnishing such exhibit.
<TABLE>
EXHIBIT INDEX
Exhibit No. Exhibit
----------- --------------
<S> <C>
2.1 Purchase and Sale Agreement, dated as of May 5, 1995, between Schering Corporation and
WJ Acquisition Corp.+(1)
2.2 Agreement for Purchase and Sale, dated as of July 5, 1996, between the Company and Pilkington
plc.+(1)
3.1(i) Amended and Restated Certificate of Incorporation.(2)
3.1(ii) Amended and Restated By-laws.(2)
4.1 Certificate representing shares of Common Stock, $0.01 par value per share.(1)
4.2 Stockholders Agreement, dated October 22, 1996, among the Company and the stockholders named
therein.(1)
4.3 Amended and Restated Registration Agreement, dated as of October 22, 1996, between the Company
and the stockholders named therein.(1)
4.4 Credit Agreement, dated as of February 19, 1997 and as amended as of September 10, 1997, among
Wesley Jessen VisionCare, Inc., Wesley-Jessen Corporation, various lending institutions, and Bankers
Trust Company, as Agent.+(3)
4.5 Security Agreement, dated as of February 19, 1997, among Wesley Jessen VisionCare, Inc., Wesley-
Jessen Corporation, certain other subsidiaries of Wesley Jessen VisionCare, Inc. and Bankers Trust
Company, as Collateral Agent.+(2)
4.6 Pledge Agreement, dated as of February 19, 1997, by Wesley Jessen VisionCare, Inc., Wesley-Jessen
Corporation and certain other subsidiaries of Wesley Jessen VisionCare, Inc. in favor of Bankers Trust
Company, as Collateral Trustee and Agent.+(2)
4.7 Subsidiary Guaranty, dated as of February 19, 1997, made by each subsidiary of Wesley-Jessen
Corporation named therein and Bankers Trust Company, as Agent.(2)
4.8 Subordinated seller's note, dated as of October 2, 1996, by Wesley-Jessen Corporation in favor of
Pilkington plc.(1)
10.1 Wesley Jessen VisionCare, Inc. 1997 Stock Incentive Plan.(2)
10.2 Wesley Jessen VisionCare, Inc. Non-Employee Director Stock Option Plan.(2)
10.3 Amended and Restated Advisory Agreement, dated as of October 2, 1996, between Wesley-Jessen
Corporation and Bain Capital, Inc.(1)
10.4 Stock Purchase Agreement, dated as of June 28, 1995, among Wesley-Jessen Holding, Inc. and the
various purchasers named therein.(1)
10.5 Agreement, dated as of December 21, 1992, between Wesley-Jessen Corporation and Tech Medical
Inc., regarding casting cups, as amended.(1)
10.6 Employment Agreement, dated June 28, 1995, between the Company and Kevin J. Ryan.(1)
10.7 Employment Agreement, dated June 28, 1995, between the Company and Edward J. Kelley.(1)
10.8 Wesley-Jessen Holding, Inc. 1995 Stock Purchase and Option Plan.(1)
10.9 Wesley-Jessen Holding, Inc. 1996 Stock Option Plan.(1)
10.10 Management Agreement, effective as of June 28, 1995 and dated as of April 5, 1996, by and between
the Company and Kevin J. Ryan (with an attached schedule setting forth the terms of other Named
Executives).(1)
10.11 Indemnification Agreement, dated as of March 4, 1997 and effective as of February 12, 1997, between
Kevin J. Ryan and the Company with an attached schedule listing the other officers and directors who
entered into such an agreement.(2)
10.12 Lease agreements relating to the Company's Southampton, United Kingdom manufacturing facility.(1)
10.13 Lease agreements relating to the Company's San Diego, California manufacturing facility.(1)
10.14 Wesley-Jessen Corporation Professional Incentive Program (1996).(1)
10.15 Wesley Jessen VisionCare, Inc. Employee Stock Discount Purchase Plan.(2)
10.16 Asset Purchase Agreement, dated as of January 24, 1997, by and among Wesley-Jessen Corporation,
PBH, Inc. and The Cooper Companies, Inc.+(2)
10.17 Unsecured promissory note, dated as of May 7, 1997, by Kevin J. Ryan in favor of Wesley-Jessen
Corporation.(4)
11.1 Earnings Per Share.
21.1 Subsidiaries of the Company.(1)
23.1 Consent of Price Waterhouse LLP.
27.1 Financial Data Schedule.
</TABLE>
________________
(1) Incorporated by reference to the applicable exhibit to the Registrant's
Registration Statement on Form S-1, Registration No. 333-17353.
(2) Incorporated by reference to the applicable exhibit to the Registrant's
Quarterly Report on Form 10-Q for the quarterly period ended March 31,
1997, File No. 0-22033.
(3) Incorporated by reference to the applicable exhibit to the Registrant's
Quarterly Report on Form 10-Q for the quarterly period ended September 27,
1997, File No. 0-22033.
(4) Incorporated by reference to the applicable exhibit to the Registrant's
Registration Statement on Form S-1, Registration No. 333-32493.
+ The Company agrees to furnish supplementally to the Commission a copy of
any omitted schedule or exhibit to such agreement upon request by
Commission.
(b) Reports on Form 8-K.
None
29
<PAGE>
REPORT OF INDEPENDENT ACCOUNTANTS--COMPANY
To the Board of Directors and Stockholders
of Wesley Jessen VisionCare, Inc.
In our opinion, the accompanying consolidated balance sheets and the related
consolidated statements of operations, of cash flows and of changes in
stockholders' equity present fairly, in all material respects, the financial
position of Wesley Jessen VisionCare, Inc. and its subsidiaries at December 31,
1996 and 1997, and the results of their operations and their cash flows for the
period from June 29, 1995 (inception) through December 31, 1995 and for each of
the two years in the period ended December 31, 1997 in conformity with generally
accepted accounting principles. These financial statements are the
responsibility of the Company's management; our responsibility is to express an
opinion on these financial statements based on our audits. We conducted our
audits of these statements in accordance with generally accepted auditing
standards which require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements, assessing the
accounting principles used and significant estimates made by management, and
evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for the opinion expressed above.
PRICE WATERHOUSE LLP
Chicago, Illinois
February 20, 1998
30
<PAGE>
REPORT OF INDEPENDENT ACCOUNTANTS--PREDECESSOR
To the Board of Directors and Stockholders
of Wesley Jessen VisionCare, Inc.
In our opinion, the accompanying consolidated statements of operations and of
cash flows present fairly, in all material respects, the results of operations
and the cash flows of the Wesley-Jessen contact lens business of Schering-Plough
Corporation (predecessor of Wesley Jessen VisionCare, Inc.--see Note 1) for the
period from January 1, 1995 through June 28, 1995 in conformity with generally
accepted accounting principles. These financial statements are the
responsibility of the management of Wesley Jessen VisionCare, Inc. and its
subsidiaries; our responsibility is to express an opinion on these financial
statements based on our audit. We conducted our audit of these statements in
accordance with generally accepted auditing standards which require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements, assessing the accounting principles used and significant estimates
made by management, and evaluating the overall financial statement presentation.
We believe that our audit provides a reasonable basis for the opinion expressed
above.
PRICE WATERHOUSE LLP
Chicago, Illinois
September 17, 1996
31
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
<TABLE>
<CAPTION>
Predecessor Company
----------- ------------------------------------------------
January 1 June 29 Twelve Months
through through -------------------------------
June 28, December 31, December 31, December 31,
1995 1995 1996 1997
----------- ------------ ------------- -------------
<S> <C> <C> <C> <C>
Net sales................................................ $ 51,019 $ 54,315 $ 156,752 $ 282,178
----------- ----------- ---------- ------------
Operating costs and expenses:
Cost of goods sold................................... 20,871 19,916 43,152 92,780
Cost of goods sold - inventory step-up .............. - 33,929 20,706 22,666
Marketing and administrative......................... 43,236 29,476 88,274 137,650
Research and development............................. 4,569 2,524 7,178 11,997
Amortization of intangibles.......................... 2,736 (392) (784) (862)
----------- ----------- ---------- ------------
Income (loss) from operations............................ (20,393) (31,138) (1,774) 17,947
Other (income) expense:
Interest income ..................................... - - - (522)
Interest expense..................................... - 2,599 5,385 6,081
Financing charge..................................... 3,511 - - -
Other income, net.................................... (1,360) - (3,051) -
----------- ----------- ---------- ------------
Income before income taxes and extraordinary loss........ (22,544) (33,737) (4,108) 12,388
Income tax benefit (expense)............................. 9,401 14,022 3,037 (4,188)
----------- ----------- ---------- ------------
Net income (loss) before extraordinary loss....................(13,143) (19,715) (1,071) 8,200
Extraordinary loss, net of related income tax benefit.... - - (1,671) (4,902)
----------- ----------- ---------- ------------
Net income (loss)........................................ $ (13,143) $ (19,715) $ (2,742) $ 3,298
=========== ============ ========== ============
Income (loss) per common share:
Basic
Net income (loss) before extraordinary loss....................... $ (1.37) $ (0.07) $ 0.49
Extraordinary loss, net of income tax benefit..................... $ - $ (0.12) $ (0.29)
Net income (loss)................................................. $ (1.37) $ (0.19) $ 0.20
Diluted
Net income (loss) before extraordinary loss....................... $ (1.37) $ (0.07) $ 0.45
Extraordinary loss, net of income tax benefit..................... $ - $ (0.12) $ (0.27)
Net income (loss)................................................. $ (1.37) $ (0.19) $ 0.18
Weighted average common shares outstanding
Basic............................................................. 14,416 14,638 16,898
Diluted........................................................... 14,416 14,638 18,451
</TABLE>
The accompanying notes are an integral part of these financial statements.
32
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share amounts)
<TABLE>
<CAPTION>
December 31,
--------------------
1996 1997
-------- --------
<S> <C> <C>
ASSETS
------
Current assets:
Cash and cash equivalents........................................... $ 7,073 $ 4,759
Accounts receivable - trade, net.................................... 38,869 42,642
Other receivables................................................... 5,155 4,773
Inventories......................................................... 69,139 49,262
Deferred income taxes............................................... 20,119 18,102
Prepaid expenses.................................................... 9,531 7,675
Assets held for sale................................................ 7,500 1,222
-------- --------
Total current assets.......................................... 157,386 128,435
-------- --------
Property, plant and equipment, net...................................... 10,125 21,480
Other assets............................................................ 1,346 6,894
Deferred income taxes................................................... 4,227 10,838
Notes receivable........................................................ - 2,773
Capitalized financing fees, net......................................... 7,516 2,656
-------- --------
Total assets.................................................. $180,600 $173,076
======== ========
LIABILITIES AND STOCKHOLDERS' EQUITY
------------------------------------
Current liabilities:
Trade accounts payable.............................................. $ 12,434 $ 14,229
Accrued compensation and benefits................................... 16,633 19,806
Accrued advertising................................................. 3,751 4,113
Other accrued liabilities........................................... 20,938 11,212
Transition reserve.................................................. 18,894 11,225
Income taxes payable................................................ 6,989 2,015
-------- --------
Total current liabilities..................................... 79,639 62,600
-------- --------
Negative goodwill, net.................................................. 10,577 13,681
Long term debt.......................................................... 102,975 57,000
Other liabilities....................................................... 701 2,949
-------- --------
Total liabilities............................................. 193,892 136,230
-------- --------
Commitments and contingencies (Note 13)
Stockholders' equity
Common stock, $.01 par value, 50,000,000 shares authorized, 14,276,028
and 17,736,011 issued and outstanding at December 31, 1996 and
December 31, 1997, respectively................................... 143 177
Additional paid in capital.......................................... 7,654 56,390
Accumulated deficit................................................. (22,457) (19,159)
Cumulative translation adjustment................................... 1,368 (562)
-------- --------
Total stockholders' equity (deficit).......................... (13,292) 36,846
-------- --------
Total liabilities and stockholders' equity.................... $180,600 $173,076
======== ========
</TABLE>
The accompanying notes are an integral part of these financial statements.
33
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
<TABLE>
<CAPTION>
Predecessor Company
----------- ------------------------------------------
January 1 June 29, Twelve Months Ended
through through ---------------------------
June 28, December 31, December 31, December 31,
1995 1995 1996 1997
----------- ------------ ------------ ------------
<S> <C> <C> <C> <C>
Operating activities:
Net income (loss) .............................................. $(13,143) $(19,715) $ (2,742) $ 3,298
Adjustments to reconcile net income (loss) to net cash
provided by (used in) operating activities:
Extraordinary loss on early extinguishment of debt ......... -- -- 2,764 7,428
Depreciation expense ....................................... 3,871 -- 462 901
Purchased inventory step-up ................................ -- 33,929 20,706 22,666
Amortization of intangible assets .......................... 2,736 -- -- --
Amortization of capitalized financing fees ................. -- 291 699 508
Amortization of negative goodwill .......................... -- (392) (784) (862)
Gain (loss) on disposal of property, plant, and equipment .. 6 -- 187 (120)
Stock compensation ......................................... -- -- -- 257
Changes in balance sheet items:
Accounts receivable--trade, net ............................ 2,430 409 5,625 (3,941)
Other receivables .......................................... 455 (343) 799 (545)
Inventories ................................................ (8,857) 4,668 402 (3,723)
Deferred income taxes ...................................... -- (15,245) (6,087) (1,622)
Prepaid expenses ........................................... 1,457 (962) (1,664) (1,192)
Other assets ............................................... (688) -- 83 (491)
Notes receivable ........................................... -- -- -- (1,227)
Trade accounts payable ..................................... (1,388) (1,614) (4,690) 2,179
Accrued liabilities ........................................ 3,286 1,786 1,883 (14,139)
Other liabilities .......................................... -- -- 145 2,181
Income taxes payable ....................................... -- 1,223 1,450 (4,679)
-------- -------- -------- ---------
Cash provided by (used in) operating activities ........ (9,835) 4,035 19,238 6,877
-------- -------- -------- ---------
Investing activities:
Net assets acquired (exclusive of cash) ........................ -- (46,653) (61,816) --
Proceeds from Natural Touch sale ............................... -- -- -- 6,000
Capital expenditures ........................................... (1,959) (893) (6,617) (16,298)
Proceeds from the sale of property, plant and equipment ........ 302 -- 427 417
-------- -------- -------- ---------
Cash used in investing activities ...................... (1,657) (47,546) (68,006) (9,881)
-------- -------- -------- ---------
Financing activities:
Issuance of stock .............................................. -- 7,525 272 48,513
Proceeds from long term debt ................................... -- 43,000 122,255 150,000
Payment of financing fees ...................................... -- (3,492) (7,778) (3,076)
Payments of long term debt ..................................... -- (1,000) (61,380) (194,375)
Advances from Schering-Plough, net ............................. 11,272 -- -- --
-------- -------- -------- ---------
Cash provided by financing activities .................. 11,272 46,033 53,369 1,062
-------- -------- -------- ---------
Effect of exchange rates on cash and cash equivalents .......... -- -- (50) (372)
Net increase (decrease) in cash and cash equivalents ........... (220) 2,522 4,551 (2,314)
Cash and cash equivalents:
Beginning of period ............................................ 2,535 -- 2,522 7,073
-------- -------- -------- ---------
End of period .................................................. $ 2,315 $ 2,522 $ 7,073 $ 4,759
======== ======== ======== =========
Supplemental disclosure of cash flow information
Cash paid during the period for interest ....................... $ -- $ 1,400 $ 4,359 $ 6,287
======== ======== ======== =========
Cash paid during the period for taxes, net ..................... $ -- $ -- $ 744 $ 7,474
======== ======== ======== =========
</TABLE>
The accompanying notes are an integral part of these financial statements.
34
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(in thousands, except share amounts)
<TABLE>
<CAPTION>
Class L
Common Stock Common Stock Additional Cumulative
------------------ -------------------- Paid in Accumulated Translation
Shares Amount Shares Amount Capital Deficit Adjustment
------ ------ ------ ------ ------- ------- ----------
<S> <C> <C> <C> <C> <C> <C> <C>
Balance at June 29, 1995..................... - $ - - $ - $ - $ - $ -
Issuance of stock............................ 429,177 4 3,862,604 39 7,739 - -
Stock subscription receivable................ - - - (1) (256) - -
Net loss..................................... - - - - - (19,715) -
-------- ------ ----------- ------ -------- ----------- ----------
Balance at December 31, 1995................. 429,177 4 3,862,604 38 7,483 (19,715) -
Issuance of stock............................ 823 - 7,396 - 15 - -
Stock subscription receivable................ - - - 1 256 - -
Currency translation adjustment.............. - - - - - - 1,368
Net loss..................................... - - - - - (2,742) -
Exchange of stock............................ (108,933) (1) 220,582 2 - - -
Retroactive effect of February 12, 1997
Class L Common Stock Reclassification..... (321,067) (3) 1,460,517 15 - - -
Retroactive effect of February 12, 1997
Common Stock split........................ - - 8,724,929 87 (100) - -
-------- ------ ----------- ------ -------- ----------- ----------
Balance at December 31, 1996................. - - 14,276,028 143 7,654 (22,457) 1,368
Issuance of stock ........................... - - 3,459,983 34 47,261 - -
Stock compensation .......................... - - - - 257 - -
Stock option related tax benefit............. - - - - 1,218 - -
Currency translation adjustment.............. - - - - - - (1,930)
Net income ................................. - - - - - 3,298 -
-------- ------ ----------- ------ -------- ----------- ----------
Balance at December 31, 1997 ................ - - 17,736,011 $ 177 $ 56,390 ($19,159) $ (562)
======== ====== =========== ====== ======== =========== ==========
</TABLE>
<TABLE>
<CAPTION>
Total
Stockholders
Equity
(Deficit)
-------
<S> <C>
Balance at June 29, 1995..................... $ -
Issuance of stock............................ 7,782
Stock subscription receivable................ (257)
Net loss..................................... (19,715)
------------
Balance at December 31, 1995................. (12,190)
Issuance of stock............................ 15
Stock subscription receivable................ 257
Currency translation adjustment.............. 1,368
Net loss..................................... (2,742)
Exchange of stock............................ 1
Retroactive effect of February 12, 1997
Class L Common Stock Reclassification..... 12
Retroactive effect of February 12, 1997
Common Stock split........................ (13)
------------
Balance at December 31, 1996................. (13,292)
Issuance of stock ........................... 47,295
Stock compensation .......................... 257
Stock option related tax benefit............. 1,218
Currency translation adjustment.............. (1,930)
Net income ................................. 3,298
------------
Balance at December 31, 1997 ................ 36,846
============
</TABLE>
The accompanying notes are an integral part of these financial statements
35
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Basis of presentation and description of business
Basis of presentation
The consolidated financial statements include the accounts of Wesley Jessen
VisionCare, Inc. (formerly known as Wesley Jessen Holding, Inc.), its wholly
owned subsidiary, Wesley Jessen Corporation, and Wesley Jessen Corporation's
wholly owned subsidiaries (collectively, the "Company"). Certain amounts in
previous years' financial statements have been reclassified to conform to
current presentation.
Description of business
The Company's primary business activity is the research, development,
manufacture, marketing and sale of conventional and disposable soft contact
lenses in the United States and certain other countries. The Company is
headquartered in Des Plaines, Illinois and operates in one business segment.
Wesley Jessen Acquisition
Effective June 29, 1995, Wesley-Jessen Corporation completed the acquisition
(the "Wesley Jessen Acquisition") of the Wesley-Jessen contact lens
business (the Predecessor) of Schering-Plough Corporation. As a result of the
Wesley Jessen Acquisition, Wesley-Jessen Corporation acquired certain assets
from Schering-Plough, consisting of manufacturing facilities in Des Plaines,
Illinois and Cidra, Puerto Rico, a distribution facility in Chicago,
Illinois, and a number of non-U.S. sales and service offices, assumed certain
liabilities of the Predecessor, and paid certain acquisition costs directly
attributable to the Wesley Jessen Acquisition (Note 3).
The consolidated financial statements for the period from January 1, 1995 to
June 28, 1995 of the Predecessor present the "carve-out" results of
operations and cash flows for the operations of the contact lens business of
Schering-Plough purchased by the Company. The financial information of the
Predecessor presented herein does not necessarily reflect what the results of
operations and cash flows of the Wesley-Jessen contact lens business would
have been had it operated as a stand-alone entity during the periods covered.
The IPO
On February 19, 1997, the Company completed an initial public offering
("IPO") of 2,500,000 shares of common stock at $15.00 per share. Concurrent
with the offering, the Board of Directors declared a 4.549-to-one conversion
of Class L Common Stock into Common Stock (the "Conversion") and a 3.133-to-
one split of the Common Stock (the "Split"). For balance sheet presentation
purposes the Conversion and the Split have been given effect as if they had
occurred on December 31, 1996. All per share data have been presented as if
the Conversion and Split had occurred on June 29, 1995. Additionally,
concurrent with the IPO, the Board of Directors amended the Company's
Articles of Incorporation, authorizing 5,000,000 and 50,000,000 shares of
Serial Preferred Stock and Common Stock, respectively. On March 20, 1997, the
Company sold an additional 321,000 shares of Common Stock at $15.00 per
share.
The Offering
In August, 1997, the Company completed a public offering of 4,000,000 shares
of common stock at $23.50 per share (the "Offering"). Of the 4,000,000
shares, 500,000 were offered by the Company and the remaining 3,500,000
shares were offered by certain selling stockholders.
36
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Net proceeds received by the Company, after deducting underwriting discounts,
commissions and offering expenses, were used to repay the "Pilkington Note"
(Note 9) and to reduce the Company's indebtedness under the Bank Credit
Agreement. In connection with the Offering, the Company amended its Bank
Credit Agreement (Note 9).
Some of the proceeds from the Company's 1997 Common Stock offerings were used
to retire indebtedness existing under its credit agreements (Note 9).
Supplemental basic net income per share is $0.22 for the year ended December
31, 1997; the number of shares of Common Stock whose proceeds are deemed to
be used to retire debt is 3,321,000. This calculation assumes the debt
retirement had taken place at the later of the beginning of the respective
period or the issuance of the debt. The amount of interest expense
eliminated, net of tax effects, is $0.6 million for the year ended December
31, 1997.
2. Summary of significant accounting policies
Use of estimates
The preparation of financial statements in accordance with generally accepted
accounting principles requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the period. Actual
results could differ from those estimates.
Principles of consolidation
All significant intercompany accounts and transactions have been eliminated
in consolidation.
Revenue recognition
Revenue is recognized when product is shipped. Net sales include estimates
for returns and allowances. The Company grants credit terms to its customers
consistent with normal industry practices and does not require collateral. No
individual customer accounts for more than 10 percent of sales or accounts
receivable.
Other income
Other income for the year ended December 31, 1996 includes income of $3.7
million relating to licensing of a patent by the Company.
Cash and cash equivalents
All highly liquid investments with an original maturity of three months or
less are considered to be cash equivalents. These amounts are stated at cost
which approximates fair value.
37
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Inventories
Inventories are stated at the lower of cost, determined by the first-in,
first-out method, or market value. Market value for raw materials is based on
replacement costs and for other inventory classifications on net realizable
value. Consideration is given to deterioration, obsolescence and other
factors in evaluating net realizable value.
Prepaid expenses
Prepaid expenses include sample inventory to be used for promotional
purposes. The sample value is charged to promotional expense during the
period in which the samples are shipped.
Property, plant and equipment
Property, plant and equipment is recorded at cost. Depreciation is determined
using the straight-line method over the estimated useful lives of the assets,
which are as follows (in years):
<TABLE>
<CAPTION>
Predecessor Company
----------- -------
<S> <C> <C>
Buildings and improvements 20 to 50 5 to 25
Machinery and equipment 10 to 15 7
Furniture and fixtures 8 to 12 7
Automobiles 4 3
</TABLE>
Expenditures for renewals and betterments are capitalized. Maintenance and
repairs are charged to operations.
Negative goodwill
Negative goodwill resulting from the Wesley Jessen Acquisition (Note 1) and
the Barnes-Hind Acquisition (Note 3) is being amortized on a straight-line
basis as a credit to income over a period of fifteen years. Negative goodwill
was $11.4 million, $10.6 million and $13.7 million, net of $0.4 million, $1.2
million and $2.0 million of accumulated amortization, at December 31, 1995,
1996 and 1997 respectively.
Capitalized financing fees
Capitalized financing fees are amortized over the term of the underlying debt
utilizing the interest method.
Research and development costs
Expenditures related to the development of new products and processes,
including significant improvements and refinements of existing products, are
expensed as incurred.
38
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Foreign currency translation
The functional currency of each of the Company's and the Predecessor's
foreign subsidiaries is the local currency of its respective country. Asset
and liability accounts of each entity are translated at the exchange rate in
effect at each period-end, and income and expense accounts are translated at
average exchange rates prevailing during the period. Gains and losses
resulting from the translation of these foreign currency financial statements
are included in the cumulative translation adjustment in stockholders'
equity.
Income taxes
The Company accounts for income taxes in accordance with Statement of
Financial Accounting Standards No. 109, "Accounting for Income Taxes." Under
this method, deferred tax assets and liabilities are recognized for the
expected future tax consequences, utilizing currently enacted tax rates, of
temporary differences between the carrying amounts and the tax bases of
assets and liabilities. Deferred tax assets are recognized, net of any
necessary valuation allowance, for the estimated future tax effects of
deductible temporary differences and tax operating loss and credit
carryforwards.
The Predecessor's operations were included in Schering-Plough's consolidated
U.S. federal tax returns. The Predecessor's provision for income taxes has
been determined as if the Predecessor had filed separate tax returns for the
period presented; all U.S. income taxes, including deferred taxes, were
settled with Schering-Plough on a current basis through the Schering-Plough
investment account, and Schering-Plough utilized the tax losses generated by
the Predecessor. The income tax attributes of the Predecessor did not carry
over to the Company.
Concentration of credit risk
The Company provides credit, in the normal course of business, to
distributors, optical store chains and physicians' offices. The Company
performs ongoing credit evaluations of its customers and maintains reserves
for potential credit losses.
Fair value of financial instruments
Cash, accounts receivable, accounts payable, and accrued liabilities are
reflected in the financial statements at amounts which approximate fair
value, primarily because of the short-term maturity of those instruments. The
Company believes that due to the adjustable interest rates applicable to its
long-term debt, the fair value approximates the carrying value of the
obligations.
Earnings per share
The company calculates earnings per share in accordance with Statement of
Financial Accounting Standards No. 128, "Earnings per Share." The difference
between the weighted average shares used in the computation of basic and
diluted earnings per share for the year ended December 31, 1997 is the
dilutive effect of outstanding stock options, using the treasury stock method
from the date of grant. Weighted average shares used in the computation for
all other periods do not include the effect of these stock options, as the
effect would be antidilutive.
39
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
3. Acquisitions
The Wesley Jessen Acquisition was completed for a total purchase price of
$76.6 million, consisting of cash paid of $47.0 million and liabilities
assumed of $29.6 million. The Wesley Jessen Acquisition was financed by $43.0
million of bank debt and $7.5 million of proceeds from the issuance of the
Company's common stock.
On October 2, 1996 the Company acquired the contact lens business of
Pilkington plc, operating as the Pilkington Barnes Hind Group ("the Barnes-
Hind Acquisition"). Aggregate consideration for the acquisition of $62.4
million was comprised of $57.4 million in cash and a $5.0 million
subordinated promissory note (Note 9). In addition, the Company paid
acquisition related fees of $2.9 million and assumed liabilities of $55.3
million. The cash portion of the purchase price was financed by the proceeds
from the Barnes-Hind Acquisition financing (Note 9).
The purchase method of accounting was used to record the acquisitions. The
results of operations of the acquired companies have been included in the
results of operations of the Company since the acquisition date. The excess
of the estimated fair values of the assets acquired over the purchase price
paid for the Wesley Jessen Acquisition of $11.8 million has been recorded as
negative goodwill (Note 2). In September, 1997 the Company negotiated a
purchase price reduction for the Barnes-Hind Acquisition of $1.6 million with
Pilkington plc based on specific net current asset measures as of the closing
date. As a result, the purchase price of Barnes-Hind, after taking into
consideration additional acquisition related fees and expenses, decreased by
$0.1 million. Additionally, certain pension valuations associated with
Barnes-Hind were completed in the third quarter of 1997. Management also
revised the operational details and related cost estimates of its plans to
integrate Barnes-Hind operations. These changes in estimates resulted in
recognition of negative goodwill of $4.0 million (Note 2) , which will be
amortized to income through June, 2010.
In connection with the Barnes-Hind Acquisition, the Company entered into a
voluntary consent order with the Federal Trade Commission which provided,
among other things, that the Company divest Barnes-Hind's U.S. Natural Touch
Product Line. On March 17, 1997, the Company completed the sale of the
product line for which, it received aggregate consideration of $7.5 million,
consisting of $3.0 million in cash and a four-year $4.5 million promissory
note. The promissory note accrues compounded interest at a rate of 12% per
annum, 8% of which is paid currently and 4% of which is payable-in-kind. As
part of the sale, the Company entered into a supply agreement pursuant to
which the Company will supply the purchaser with Natural Touch lenses for
sale in the United States. On July 31, 1997, the purchaser made a voluntary
prepayment of $3.0 million plus accrued interest on the promissory note.
40
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Pro forma results (unaudited)
The unaudited pro forma results of operations for the Company are set out below,
giving pro forma effect to; (i) the Wesley Jessen Acquisition; (ii) the Barnes-
Hind Acquisition; (iii) the Barnes-Hind Acquisition Financing described in Note
9; (iv) the estimated recurring cost savings to the Company from facilities and
personnel rationalizations; (v) elimination of non-recurring increases to cost
of goods sold as a result of applying purchase accounting to inventories; (vi)
the divestiture of Barnes-Hind's U.S. Natural Touch Product Line; and (vii)
adjusting the income tax (expense) benefit to an assumed effective rate of 34%,
each as if the transactions had occurred as of January 1, 1995 (in thousands
except per share data):
<TABLE>
<CAPTION>
Year ended Year ended
December 31, December 31,
1995 1996
------------ -------------
<S> <C> <C>
Net sales $ 230,997 $ 249,999
============ =============
Net income (loss) before extraordinary loss $ (1,523) $ 12,048
============ =============
Extraordinary loss, net of income tax benefit $ - $ (1.671)
============ =============
Net income (loss) $ (1,523) $ 10,377
============ =============
Basic net income (loss) per common share
Net income (loss) before extraordinary loss $ (0.11) $ 0.82
============ =============
Extraordinary loss, net of income tax benefit $ - $ (0.11)
============ =============
Net income (loss) $ (0.11) $ 0.71
============ =============
Weighted average shares used in computation of
basic net income (loss) per common share 14,416 14,638
============ =============
Diluted net income (loss) per common share
Net income (loss) before extraordinary loss $ (0.11) $ 0.76
============ =============
Extraordinary loss, net of income tax benefit $ - $ (0.11)
============ =============
Net income (loss) $ (0.11) $ 0.65
============ =============
Weighted average shares used in computation of
diluted net income (loss) per common share 14,416 15,863
============ =============
</TABLE>
The pro forma results are not necessarily indicative of what actually would have
occurred if the Barnes-Hind Acquisition had been in effect for the periods
presented and are not intended to be a projection of future results.
41
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
4. Transition Reserve and Restructuring Charge
In connection with the Barnes-Hind Acquisition, management approved a plan to
integrate the acquired operations, for which an accrual of $20.4 million
("transition reserve") was established in purchase accounting. The transition
reserve includes costs related to the closure of the Barnes-Hind corporate
offices in Sunnyvale, California which was completed in the third quarter of
1997 and resulted in the termination of 123 employees. In addition, management
plans to curtail certain manufacturing activities in San Diego, California which
will comprise reductions in direct labor, quality assurance, maintenance and
other manufacturing functions as well as site support and administrative
operations, including distribution, customer service, credit and collections.
These activities will be transferred to other Company locations and will result
in the termination of 291 employees (of whom 108 had been terminated as of
December 31, 1997). Payments related to the transition reserve are as follows
(in thousands):
<TABLE>
<CAPTION>
Lease Facility
Employee Termination Restoration
Related Costs Costs and Other Costs Total
------------------- --------------------- ----------------- ---------
<S> <C> <C> <C> <C>
Transition reserve at
October 2, 1996 $16,772 $2,243 $1,385 $20,400
Charges against reserve 1,149 223 134 1,506
------- ------ ------ -------
Transition reserve at
December 31, 1996 15,623 2,020 1,251 18,894
Charges against reserve 6,072 1,323 274 7,669
------- ------ ------ -------
Transition reserve at
December 31, 1997 $ 9,551 $ 697 $ 977 $11,225
======= ====== ====== =======
</TABLE>
In addition to the transition plan, the Company committed to a plan to
restructure the Wesley Jessen operations following the Barnes-Hind Acquisition,
resulting in a $3.4 million charge in the fourth quarter of 1996 ("restructuring
reserve"). Pursuant to the restructuring plan, the Chicago distribution
facilities were consolidated with those at Des Plaines, Illinois in October,
1997. The restructuring reserve totaling $1.2 million at December 31, 1997,
consists of costs related to employee termination, lease termination and other
restructuring costs associated with the consolidation of certain Wesley Jessen
facilities in Europe with facilities acquired in the Barnes-Hind Acquisition.
Usage of the restructuring reserve is as follows (in thousands):
<TABLE>
<CAPTION>
Employee Lease
Related Termination Other
Costs Costs Costs Total
-------- ----------- ------ ------
<S> <C> <C> <C> <C>
Restructuring reserve at
December 31, 1996 $813 $897 $1,690 $3,400
Charges against reserve 437 235 1,480 2,152
---- ---- ------ ------
Restructuring reserve at
December 31, 1997 $376 $662 $ 210 $1,248
==== ==== ====== ======
</TABLE>
42
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
5. Accounts receivable--trade, net
Accounts receivable--trade, net consist of the following (in thousands):
<TABLE>
<CAPTION>
December 31, December 31,
1996 1997
------------ ------------
<S> <C> <C>
Trade receivables $ 56,480 $ 59,293
Less allowances:
Doubtful accounts (6,989) (6,290)
Sales returns and adjustments (10,622) (10,361)
-------- --------
$ 38,869 $ 42,642
======== ========
</TABLE>
6. Inventories
consist of the following at (in thousands):
<TABLE>
<CAPTION>
December 31, December 31,
1996 1997
------------ ------------
<S> <C> <C>
Raw materials $ 6,073 $ 3,558
Work-in-process 8,958 7,613
Finished goods 54,108 38,091
------- -------
$69,139 $49,262
======= =======
</TABLE>
In connection with the Wesley Jessen Acquisition and the Barnes-Hind
Acquisition, under the purchase method of accounting, the Company's total
inventories were written up to fair value at the date of acquisition by $40.6
million and $36.7 million, respectively. Of these amounts, $33.9 million, $20.7
million and $22.7 million was charged to cost of goods sold during the period
June 29, 1995 through December 31, 1995 and the years ended December 31, 1996
and 1997, respectively.
7. Property, plant and equipment
Property, plant and equipment consist of the following (in thousands):
<TABLE>
<CAPTION>
December 31, December 31,
1996 1997
------------ ------------
<S> <C> <C>
Buildings and improvements $ 1,230 $ 8,369
Machinery, equipment, furniture and
fixtures 6,257 10,246
Construction-in-progress 3,034 4,159
------- -------
10,521 22,774
Less accumulated depreciation (396) (1,294)
------- -------
$10,125 $21,480
======= =======
</TABLE>
43
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
8. Advertising costs
The Predecessor and the Company participate in several cooperative advertising
programs with customers. The costs incurred under these programs are accrued and
expensed at the inception of the contract. All of the Predecessor's and the
Company's other production costs of advertising are expensed the first time the
advertising takes place. Advertising expense for the period from January 1, 1995
through June 28, 1995, the period from June 29, 1995 through December 31, 1995,
and for the years ended December 31, 1996 and 1997 was $11.7 million, $7.2
million, $14.0 million and $17.9 million, respectively.
9. Long-term debt
Wesley Jessen Acquisition financing
On June 28, 1995, the Company entered into a $55 million credit agreement,
consisting of a $30 million term loan payable in quarterly installments,
commencing December 31, 1995, and a $25 million revolving credit note, both of
which were due June 30, 2001. Interest on the term loan was computed on a
floating rate based on LIBOR while the revolver was based on a fixed rate. At
December 31, 1995, the Company's weighted average borrowing rate was 9.3%.
This agreement was refinanced on October 2, 1996.
Barnes-Hind Acquisition financing
On October 2, 1996, in connection with the Barnes-Hind Acquisition, the Company
replaced its long-term borrowing arrangement with the following new credit
facilities:
$45 million revolving credit facility due February 28, 2002
$45 million Term Loan A due February 28, 2002
$50 million Term Loan B due February 29, 2004
In connection with the refinancing, the Company recognized an extraordinary loss
of $2.8 million ($1.7 million, net of income tax benefit), relating to the
write-off of capitalized financing fees incurred in connection with the Wesley
Jessen Acquisition financing. Additionally, the Company incurred and capitalized
financing fees of approximately $7.8 million which were being amortized over the
term of the new credit facilities.
At December 31, 1996, the applicable borrowing rates were as follows: Term Loan
A, 8.25%; Term Loan B, 8.75%; and revolving credit facility, 10.0%.
Additionally, the Company was required to pay a commitment fee of 0.5% of the
unutilized commitments under the revolving credit facility; the unutilized
portion at December 31, 1996 was $42.0 million. The credit facilities were
guaranteed by the Company and secured by the capital stock and substantially all
assets and property of all its direct and indirect domestic subsidiaries. These
facilities were refinanced on February 19, 1997.
44
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Additionally, as part of the consideration paid for the Barnes-Hind Acquisition
the Company entered into a $5.0 million promissory note with Pilkington plc (the
"Pilkington Note") which bore interest at 8.0% compounded annually and payable
at maturity. The note was to mature on February 1, 2005 subject to certain
acceleration provisions. In September, 1997, the note was reduced by $1.6
million, based on purchase price negotiations, and the remaining principal was
repaid.
Initial Public Offering-refinancing
On February 19, 1997, in connection with the IPO, the Company replaced its long-
term borrowing arrangements with the following new credit facilities (the "Bank
Credit Agreement"):
$35 million revolving loan facility due February 19, 2002
$65 million Term Loan due February 19, 2002
In connection with the refinancing, the Company recognized an extraordinary loss
of $7.4 million ($4.9 million, net of income tax benefit), relating to the
write-off of capitalized financing fees incurred in connection with the Barnes-
Hind Acquisition Financing. Additionally, the Company incurred and capitalized
financing fees of approximately $2.5 million.
On September 10, 1997, in connection with the Offering, the Bank Credit
Agreement was amended to consist of a $135.0 million revolving loan facility
(the "Amended Bank Credit Agreement"), the availability of which will be reduced
by $20.0 million on September 11, 2000 and $20.0 million on September 11, 2001.
The facility matures on September 11, 2002.
In conjunction with the amendment, an additional $0.6 million of financing fees
were incurred and capitalized. These fees are being amortized over the term of
the Amended Bank Credit Agreement.
Amounts borrowed under the Amended Bank Credit Agreement bear interest at either
the Base Rate (higher of (i) 0.5% in excess of the Federal Reserve reported
adjusted certificate of deposit rate and (ii) the lender's prime lending rate
plus a margin up to 0.5% based on leverage ratios calculated as of certain
dates) or the Eurodollar Rate as determined by the lenders plus a margin of
0.375% to 1.500% based on the type of loan and leverage ratios calculated as of
certain dates as defined in the credit agreement. At December 31, 1997, the
weighted average borrowing rate was 6.72%. Additionally, the Company is
required to pay a commitment fee on the unutilized revolving loan commitments,
as defined in the credit agreement, ranging from 0.175% to 0.400% based on
leverage ratios calculated as of certain dates. The unutilized portion of the
credit facilities at December 31, 1997 was $78.0 million. The credit facilities
are guaranteed by each of the Company's domestic subsidiaries and secured by
essentially all assets of the domestic subsidiaries.
The Amended Bank Credit Agreement contains a number of covenants restricting the
Company and its subsidiaries with respect to the incurrence of indebtedness, the
creation of liens, the consummation of certain transactions such as sales of
substantial assets, mergers or consolidations, the making of certain
investments, capital expenditures, and payment of dividends. In addition, the
Company is required to maintain certain financial covenants and ratios.
45
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Interest rate instrument
The Company has purchased an interest rate cap on $35.0 million of notional
principal amount at 8.5%, which expires on December 31, 1999. The cap is
intended to provide partial protection to the Company from potential exposure
relating to its variable rate debt instruments.
10. Stockholders' deficit
Pre-IPO capital structure
The Company's authorized capital stock consisted of 600,000 shares of Class L
Common Stock, par value $.01 per share ("Class L Common"), and 5,400,000 shares
of Common Stock, par value $.01 per share ("Common Stock"). Concurrent with the
Wesley Jessen Acquisition, the Company issued 415,000 shares of Class L Common
(issued at $17.41 per share) and 3,735,000 shares of Common Stock (issued at
$0.081 per share).
Holders of Class L Common and Common Stock were entitled to one vote per share
on all matters to be voted on by the Company's stockholders, and the holders of
both classes of stock vote together as a single class. The outstanding shares
of one class of stock could not be the subject of a stock split or a stock
dividend unless the outstanding shares of the other class are similarly
affected.
Holders of Class L Common were entitled to a preferential payment ("Yield") in
the amount of 12.5% per year on the original cost paid for the shares ($17.41
per share) plus any accumulated and unpaid Yield thereon. The Yield accumulated
until such time as distributions were made by the Company. No distributions
were made by the Company during the periods ended December 31, 1995 and 1996 and
the accumulated and unpaid Yield at December 31, 1995 and 1996, amounted to $0.5
million and $1.5 million, respectively. As part of the Conversion this unpaid
Yield was converted to Common Stock.
Post-IPO capital structure
Effective February, 1997, the Company's authorized capital stock consists of
50,000,000 shares of Common Stock and 5,000,000 shares of Serial Preferred
Stock.
Holders of the Common Stock shares, subject to the prior rights of the Serial
Preferred Stock, are entitled to receive dividends, are entitled to one vote per
share and are entitled to receive, pro rata, the assets of the Company which are
legally available for distribution, after payment of all debts and other
liabilities and subject to the prior rights of any holders of Serial Preferred
Stock then outstanding.
The Company's Board of Directors may, without further action by the Company's
stockholders, direct the issuance of shares of Serial Preferred Stock and may at
the time of issuance, determine the rights, preferences and limitations of each
series.
46
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Stock options
As permitted, the Company applies Accounting Principles Board Opinion 25 and
related Interpretations in accounting for its stock-based compensation plan, and
recognized expense of $0.3 million for the year ended December 31, 1996. Had
compensation cost for the Company's stock-based compensation plan been
determined based on the fair value of the options at the grant dates for the
awards under the plan consistent with the alternative method of Statement of
Financial Accounting Standards No. 123, "Accounting for Stock-Based
Compensation," the pro forma effect on the Company's net loss and loss per share
for the period ended December 31, 1995 would not have been significant. The pro
forma effect for other periods presented would have been as follows (in
thousands, except per share data):
<TABLE>
<CAPTION>
Year ended Year ended
December 31, December 31,
1996 1997
------------ ------------
<S> <C> <C>
Pro forma net income (loss)
Net income (loss) before extraordinary loss $(1,447) $ 7,785
Extraordinary loss, net of income tax benefit (1,671) (4,902)
Net income (loss) (3,118) 2,883
Pro forma basic net income (loss) per share
Net income (loss) before extraordinary loss $ (0.10) $ 0.46
Extraordinary loss, net of income tax benefit (0.12) (0.29)
Net income (loss) (0.22) 0.17
Pro forma diluted net income (loss) per share
Net income (loss) before extraordinary loss $ (0.10) $ 0.42
Extraordinary loss, net of income tax benefit (0.12) (0.27)
Net income (loss) (0.22) 0.15
</TABLE>
47
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
1995 and 1996 stock option plans
The Board of Directors granted non-qualified stock options to certain members of
management for an aggregate of 2,193,051 shares of Common Stock pursuant to the
Company's 1995 Stock Purchase and Option Plan. The stock option grants are of
two types: time options and target options. Of the 783,233 time option grants,
469,940 vest in four equal annual installments beginning on June 28, 1996 and
313,293 vest in five equal annual installments beginning on April 5, 1996. The
time options were granted at the fair market value of the Common Stock on the
date of grant. The 1,409,818 target option grants are exercisable immediately
and were granted at prices that were in excess of fair market value of the
Common Stock on the date of grant. All options expire in 10 years and include
certain repurchase and participation rights which cease upon (1) a sale of the
Company or (2) sale of its Common Stock by the Company pursuant to a
Registration Statement under the Securities Act of 1933 in connection with which
Bain Capital, Inc. and affiliated investors cease to own at least 20% of the
Company.
In October, 1996, pursuant to the 1996 Stock Option Plan, the Board of Directors
authorized and granted options to purchase an aggregate of 424,519 shares of
Common Stock at an exercise price which approximates fair market value at the
date of grant. Options to purchase 267,872 shares were immediately exercisable,
and options to purchase 156,647 shares vest in five equal annual installments
beginning October 22, 1997.
1997 Stock Incentive Plan
The Wesley Jessen VisionCare, Inc. 1997 Stock Incentive Plan (the "1997 Stock
Plan") was approved by the Board of Directors in February, 1997. The 1997 Stock
Plan provides for the issuance of the following types of incentive awards: stock
options, stock appreciation rights, restricted stock, performance grants and
other types of awards. An aggregate of 800,000 shares of Common Stock of the
Company have been reserved for issuance under the 1997 Stock Plan, subject to
certain adjustments reflecting changes in the Company's capitalization. The 1997
Stock Plan provides that individual participants will be limited to receiving
awards of no more than 50,000 shares of Common Stock per year.
Options granted under the 1997 Stock Plan may be subject to time vesting and
certain other restrictions. Subject to certain exceptions, the right to exercise
an option generally will terminate at the earlier of (i) the first date on which
the initial grantee of such option is not employed by the Company for any reason
other than termination without cause, death or permanent disability or (ii) the
expiration date of the option. All outstanding awards under the 1997 Stock Plan
will terminate immediately prior to consummation of a liquidation or dissolution
of the Company, unless otherwise provided by the Board. In the event of the sale
of all or substantially all of the assets of the Company or the merger of the
Company with another corporation, all restrictions on any outstanding awards
will terminate and participants will be entitled to the full benefit of their
awards immediately prior to the closing date of such sale or merger, unless
otherwise provided by the Board.
Non-Employee Director Stock Option Plan
The 1997 Non-Employee Director Stock Option Plan (the "Director Option Plan")
was approved by the Board of Directors in February 1997. The Director Option
Plan provides for the granting of options to
48
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
non-employee Directors, as defined, covering an aggregate of 250,000 shares of
Common Stock of the Company.
The Board of Directors is authorized under the Director Option Plan to make
discretionary grants of options and determine the terms and conditions of such
options. In addition, the Director Option Plan provides for an initial one-time
grant of options to purchase 10,000 shares of Common Stock to each non-employee
Director serving as a member of the board or to any new non-employee Director
upon being elected to the board. The Director Option Plan also provides that
each non-employee Director shall automatically be granted options to purchase
2,000 shares of Common Stock upon each anniversary of the Director's election to
the Board. The Director Option Plan requires that the exercise price for each
option granted under the plan must equal 100% of the fair market value of the
Company's Common Stock on the date the option is granted. The initial one-time
grants will be immediately exercisable and the annual grants will vest in three
equal installments commencing on the first anniversary of the grant date.
A summary of the Company's stock option plans as of December 31, 1995, 1996 and
1997, and changes during the periods then ended is presented below:
<TABLE>
<CAPTION>
1995 1996 1997
-------------------------- --------------------------- ---------------------------
Weighted- Weighted- Weighted-
Average Average Average
Shares Exercise Price Shares Exercise Price Shares Exercise Price
--------- -------------- --------- -------------- --------- --------------
<S> <C> <C> <C> <C> <C> <C>
Outstanding at beginning of period - $ - 2,038,658 $1.14 2,617,570 $ 2.13
Granted 2,038,658 1.14 578,912 5.63 326,700 17.24
Exercised - - - - (127,612) 0.27
Forfeited - - - - - -
--------- --------- ---------
Outstanding at end of year 2,038,658 $1.14 2,617,570 $2.13 2,816,658 $ 3.97
========= ========= =========
Options exercisable at year-end 1,306,890 $1.76 1,857,834 $2.38 2,001,695 $ 2.89
========= ========= =========
Weighted-average fair value of
options granted during the year $ - $ 2.36 $ 5.23
========= ========= =========
</TABLE>
The fair value of each option is estimated on the date of grant using the Black-
Scholes option-pricing model with the following weighted average assumptions for
options granted in 1995, 1996 and 1997, respectively: expected volatility of
24.31%, 25.69% and 31.29%; risk-free interest rate of 5.98%, 6.36% and 6.38%;
and expected lives of 7 years, 7 years and 3 years.
The following table summarizes information about stock options outstanding at
December 31, 1997:
<TABLE>
<CAPTION>
Options Outstanding Options Exercisable
----------------------------------------------------- -------------------------------
Number Weighted-Average Weighted Number Weighted-
Outstanding Remaining Average Exercisable Average
Exercise Prices at 12/31/97 Contractual Life Exercise Price at 12/31/97 Exercise Price
- - --------------- ----------- ---------------- -------------- ----------- --------------
<S> <C> <C> <C> <C> <C>
$ 0.03 682,509 7.54 years $ 0.03 259,563 $ 0.03
$ 1.18 678,021 7.55 years 1.18 678,021 1.18
$ 2.34 704,909 7.55 years 2.34 704,909 2.34
$ 7.24 424,519 8.81 years 7.24 299,202 7.24
$15.00 40,000 9.14 years 15.00 40,000 15.00
$16.75 266,700 9.35 years 16.75 - -
$28.25 20,000 9.75 years 28.25 20,000 28.25
--------- ---------- ------ --------- ------
2,816,658 7.95 years 3.97 2,001,695 2.89
========= ========== ====== ========= ======
</TABLE>
49
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Stock Purchase Plan
The Wesley Jessen VisionCare, Inc. Employee Stock Discount Purchase Plan (the
"Stock Purchase Plan") was approved by the Board of Directors in February, 1997
and provides that, subject to certain restrictions, each United States employee
of the Company will be eligible to participate in the Stock Purchase Plan if he
or she has been employed by the Company for more than six months. The Company
has reserved 500,000 shares of Common Stock for issuance in connection with the
Stock Purchase Plan and each eligible employee is entitled to purchase a maximum
of 500 shares per year. Each participating employee contributes to the Stock
Purchase Plan by choosing a payroll deduction in any specified amount, with a
minimum deduction of $25.00 per payroll period. Each participating employee's
contributions will be used to purchase shares for the employee's share account,
and the cost per share will be 85% of the price of the Company's Common Stock on
the Nasdaq National Market on specified dates.
11. Income taxes
Income (loss) before income tax benefit (expense) and extraordinary loss is as
follows (in thousands):
<TABLE>
<CAPTION>
Predecessor Company
----------- -----------------------------------------
January 1 June 29 Year Year
through through ended ended
June December December December
28, 1995 31, 1995 31, 1996 31, 1997
----------- -------- -------- --------
<S> <C> <C> <C> <C>
Domestic (including Puerto Rico) $(17,936) $(33,469) $(7,721) $20,088
International (4,608) (268) 3,613 (7,700)
-------- -------- ------- -------
$(22,544) $(33,737) $(4,108) $12,388
======== ======== ======= =======
</TABLE>
Income tax benefit (expense) is as follows (in thousands):
<TABLE>
<CAPTION>
Predecessor Company
----------- -----------------------------------------
January 1 June 29 Year Year
through through ended ended
June December December December
28, 1995 31, 1995 31, 1996 31, 1997
----------- -------- -------- --------
<S> <C> <C> <C> <C>
Current income tax benefit (expense):
Domestic federal $ 6,338 $ (872) $(2,126) $(2,694)
Domestic state and local (including Puerto Rico) 3,063 (287) (922) (1,359)
International - (64) (116) (1,757)
-------- -------- ------- -------
9,401 (1,223) (3,164) (5,810)
======== ======== ======= =======
Deferred income tax benefit (expense):
Domestic federal - 13,045 4,307 328
Domestic state and local (including Puerto Rico) - 2,228 (1,237) (994)
International - (28) 3,131 2,288
-------- -------- ------- -------
- 15,245 6,201 1,622
-------- -------- ------- -------
$ 9,401 $ 14,022 $ 3,037 $(4,188)
======== ======== ======= =======
</TABLE>
50
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Income tax benefit (expense)
No allocation of the Predecessor's income tax benefits between current and
deferred amounts has been made as all U.S. income taxes, including deferred
taxes, were settled with Schering-Plough on a current basis through the
Schering-Plough investment account. Schering-Plough utilized in full the tax
losses generated by the Predecessor. The income tax attributes of the
Predecessor did not survive the Wesley Jessen Acquisition.
Differences between the U.S. federal income tax statutory rates and the income
tax benefit (expense) recorded are attributable to the following:
<TABLE>
<CAPTION>
Predecessor Company
----------- -----------------------------------------------
January 1 June 29 Year Year
through through ended ended
June 28, December 31, December 31, December 31,
1995 1995 1996 1997
----------- ------------ ------------ ------------
<S> <C> <C> <C> <C>
Income tax statutory rate 35.0% 34.0% 35.0% (35.0%)
State and local taxes (including Puerto Rico),
net of federal tax benefit 13.6 8.4 39.4 20.5
Effect of international operations (7.2) (0.5) (4.5) (17.5)
Amortization of negative goodwill - 0.2 6.8 2.4
Other 0.3 (0.5) (2.8) (4.2)
---- ---- ---- -----
41.7% 41.6% 73.9% (33.8%)
==== ==== ==== =====
</TABLE>
Deferred tax assets and liabilities are comprised of the following (in
thousands):
<TABLE>
<CAPTION>
December 31, December 31,
1996 1997
------------ ------------
<S> <C> <C>
Deferred tax assets:
Accounts receivable valuation allowances $ 5,484 $ 6,179
Inventory reserves 695 4,746
Fixed assets 5,980 10,143
Accrued expenses 13,195 7,177
Domestic net operating losses - 4,716
Other deductible temporary differences - 934
International net operating losses 2,296 6,297
------- -------
27,650 40,192
======= =======
Deferred tax liabilities:
Prepaid pension cost - (2,485)
Puerto Rico tollgate tax (1,008) (2,470)
------- -------
Total deferred tax liabilities (1,008) (4,955)
------- -------
Valuation allowance for international net operating losses (2,296) (6,297)
------- -------
$24,346 $28,940
======= =======
</TABLE>
51
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
At December 31, 1996 and 1997, the Company has not provided a valuation
allowance against its deferred tax assets except for the asset relating to
foreign net operating losses ("NOLs") because, based upon its current operating
plans, the Company believes that it is more likely than not that the assets will
be realized through future profitable operations.
The Company has foreign NOLs which expire in four to seven years from December
31, 1997. The Company has domestic net operating losses which expire in the year
2012. A full valuation allowance has been provided against the deferred asset
relating to these NOLs as the Company believes it is more likely than not that
the benefits of the NOLs will not be realized in the future.
Estimated taxes have been provided for the Company's international operations
assuming repatriation of all available earnings. The Predecessor's and the
Company's manufacturing operations in Puerto Rico qualify for income tax credit
available under Section 936 of the Internal Revenue Code. Recent legislation
will phase out the income tax credit allowed under Section 936 over a ten year
period. The phase out period will allow a tax credit under present law through
December 31, 2001. The credit will be subject to further limitation through
December 31, 2005, and thereafter the credit is eliminated.
12. Retirement benefits
Defined benefit pension plans
Eligible employees of the Predecessor in the United States and certain other
countries were participants, along with employees of other Schering-Plough
subsidiaries, in defined benefit pension plans sponsored by Schering-Plough.
Benefits under these plans are generally based upon the participants' average
final earnings and years of credited service, and take into account governmental
retirement benefits. Pension cost allocated by Schering-Plough to the
Predecessor for the period from January 1, 1995 through June 28, 1995 was a net
credit of $0.2 million.
Effective June 29, 1995, the employees of the Company terminated participation
in the Schering-Plough pension plans. Pursuant to the Wesley Jessen Acquisition
agreement, the United States participants' pension liabilities and the related
assets were transferred from the Schering-Plough plan to a new plan, established
by the Company, the Wesley Jessen Cash Balance Pension Plan (the "Wesley Jessen
Plan"). The amounts of pension liabilities and accompanying assets transferred
from the Schering-Plough plan to the Wesley Jessen Plan, in September, 1997,
were approximately $4.8 million. Prior to the transfer to the Wesley Jessen
Plan, the pension assets earned a 7% rate of return guaranteed by Schering-
Plough.
The Wesley Jessen Plan is a defined benefit plan, effective as of January 1,
1996, covering substantially all United States employees (including Puerto
Rico). Under the Wesley Jessen Plan, the Company allocates a percentage of
compensation for each participant (annual pay credits) based upon years of
service, excluding the period June 29, 1995 to December 31, 1995 and with the
Predecessor. Additionally, the Wesley Jessen Plan provides for a specified
return (interest credits) on participants' account balances. Under the Wesley
Jessen Plan, annual pay credits and interest credits will be accumulated in
participants' accounts as the basis for their Wesley Jessen Plan benefits. The
Company will contribute actuarially determined amounts to fund Wesley Jessen
Plan benefits within regulatory minimum requirements and
52
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
maximum tax deductible limits. Vesting occurs after five years of service and
includes service during the period June 29, 1995 to December 31, 1995.
In connection with the Barnes-Hind Acquisition the Company acquired a fully
funded portion of the Pilkington VisionCare Pension Plan, a non-contributory
defined benefit pension plan, which covers substantially all Barnes Hind United
States employees. Additionally, the Company acquired an international fully-
funded contributory single-employer defined benefit pension plan covering
certain Barnes Hind employees in the United Kingdom.
Under the plans acquired in the Barnes-Hind Acquisition, benefit payments for
United States employees are based principally on earnings during the last five-
year period prior to retirement and length of service. Employees are eligible to
participate in domestic plans within one year of employment and are vested after
five years of service. For the international employees, benefits are based on
length of service and on compensation during the last ten years of service prior
to retirement. Funding is on an actuarially determined basis, to provide for the
plans' current service costs and the plans' prior service cost over their
amortization periods.
Net pension expense for the pension plans includes the following components (in
thousands):
<TABLE>
<CAPTION>
Company
----------------------------------------------------------
June 29 through Year ended Year ended
December 31, December 31, December 31,
1995 1996 1997
--------------- ------------ ------------
<S> <C> <C> <C>
Service cost - benefits earned during the period $ - $ 801 $ 2,456
Interest cost on projected benefit obligations 151 745 2,104
Actual return on plan assets (151) (1,424) (2,497)
Net amortization and deferral - 656 (195)
----- ------- -------
Net pension expense $ - $ 778 $ 1,868
===== ======= =======
</TABLE>
The following table sets forth the reconciliation of the funded status of
defined benefit plans where accumulated benefit obligations exceed plan assets
(in thousands):
<TABLE>
<CAPTION>
1996 1997
------ -------
<S> <C> <C>
Actuarial present value of benefit obligations:
Vested benefit obligations $5,017 $ 5,650
Non-vested benefit obligations 280 222
------ -------
Accumulated benefit obligations $5,297 5,872
====== =======
Plan assets at fair value $4,815 $ 5,034
Projected benefit obligations 5,433 6,087
------ -------
Plan assets less than projected benefit obligations (618) (1,053)
Unrecognized prior service cost 681 621
Unrecognized net gain (601) (860)
------ -------
Pension liability recognized $ (538) $(1,292)
====== =======
</TABLE>
53
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The following table sets forth the reconciliation of the funded status for
defined benefit plans where plan assets exceed accumulated benefit obligations
(in thousands):
<TABLE>
<CAPTION>
December 31, 1996 December 31, 1997
----------------------------- -----------------------------
Domestic International Domestic International
-------- ------------- -------- -------------
<S> <C> <C> <C> <C>
Actuarial present value of benefit obligations:
Vested benefit obligations $ 7,329 $6,508 $ 9,061 $6,273
Non-vested benefit obligations 938 - 598 -
------- ------ ------- ------
Accumulated benefit obligation $ 8,267 $6,508 $ 9,659 $6,273
======= ====== ======= ======
Plan assets at fair value $16,375 $8,647 $15,577 $8,335
Projected benefit obligation 14,872 8,411 9,855 8,107
------- ------ ------- ------
Plan assets in excess of projected benefit 1,503 236 5,722 228
obligations
Unrecognized prior service cost - - - -
Unrecognized net gain (509) (94) (268) (91)
------- ------ ------- ------
Prepaid pension cost $ 994 $ 142 $5,454 $ 137
======= ====== ======= ======
</TABLE>
Assumptions used in the actuarial computations are as follows:
<TABLE>
<CAPTION>
December 31, December 31,
1996 1997
------------ ------------
<S> <C> <C>
Domestic plans:
Discount rate 7.5% 6.75%
Expected rate of compensation increase 5.0% 5.0%
Expected rate of return on plan assets 7.0%-9.0% 9.0%
International plans:
Discount rate 8.5% 8.5%
Expected rate of compensation increase 6.5% 6.5%
Expected rate of return on plan assets 8.5% 8.5%
</TABLE>
Defined contribution plans
The Company sponsors defined contribution plans covering substantially all U.S.
employees. The plans provide for specified Company matching of participants'
contributions. Contributions charged to operations for the years ended December
31, 1996 and 1997 totaled $0.7 million and $1.5 million, respectively.
Postretirement benefits other than pensions
Eligible United States retirees of the Predecessor and their dependents were
provided postretirement health care and other benefits under benefit plans
sponsored by Schering-Plough. Eligibility for such benefits depended upon age
and years of service, and retirees shared in the cost of health care benefits.
Postretirement health care cost allocated to the Predecessor by Schering-Plough
for the period from January 1, 1995 through June 28, 1995 was $0.3 million. In
conjunction with the Wesley Jessen Acquisition, the Company did not assume any
existing retiree postretirement benefit obligation, nor does the Company offer
postretirement health care benefits to its employees.
54
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
13. Commitments and contingencies
Leases
The Company leases certain facilities and computer and other equipment under
operating leases. Total rent expense was as follows (in thousands):
<TABLE>
<CAPTION>
<S> <C>
Predecessor
The period from January 1, 1995 through June 28, 1995 $1,513
======
Company
The period from June 29, 1995 through December 31, 1995 $ 494
======
Year ended December 31, 1996 $2,554
======
Year ended December 31, 1997 $3,269
======
</TABLE>
Future minimum lease payments under non-cancelable operating leases at December
31, 1997 were as follows (in thousands):
<TABLE>
<CAPTION>
Year Ending
-----------
<S> <C>
December 31, 1998 $2,857
December 31, 1999 2,230
December 31, 2000 1,774
December 31, 2001 1,618
December 31, 2002 1,588
Thereafter 8,410
</TABLE>
Litigation
The Company has certain patent infringement, product liability, personal injury
and employment related litigation and claims pending in the normal course of its
business. Management believes that any uninsured losses resulting from the
resolution of such litigation and claims would not have a material adverse
impact on the Company's financial position or results of operations as presented
in the accompanying financial statements.
14. Related party transactions
Predecessor
Schering-Plough provided the Predecessor certain legal, audit, data processing,
engineering, insurance, facility, regulatory, and administrative services.
Charges to the Predecessor for these services are reflected in the Consolidated
Statements of Operations through June 28, 1995 and were based on allocations of
Schering-Plough's actual direct and indirect costs using varying allocation
bases as appropriate (hours worked, headcount, etc.) designed to estimate the
actual cost incurred by Schering-Plough to render these services to the
Predecessor. Management believes that the basis used for allocating such
services is reasonable, and the allocation process was consistent with the
methodology used by Schering-Plough to allocate the cost of similar services
provided to its other business units. No provision has been made for possible
incremental expenses that would have been incurred or hypothetical savings
achieved had the
55
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Predecessor operated as an independent entity. These charges are included in
marketing and administrative expenses and are summarized as follows (in
thousands):
<TABLE>
<CAPTION>
January 1, through
June 28, 1995
------------------
<S> <C>
Allocations:
General and administrative $1,130
Legal 789
Compensation and benefits 61
Direct charges:
Insurance 1,825
------
$3,805
======
</TABLE>
The Predecessor's consolidated statements of operations also include a financing
charge from Schering-Plough based upon 11% of receivables outstanding and
inventories on-hand throughout the period. This charge amounted to $3.5 million
for the period from January 1, 1995 through June 28, 1995.
A summary of changes in Schering-Plough's net investment in the Predecessor is
as follows (in thousands):
<TABLE>
<S> <C>
Excess of assets over liabilities at December 31, 1994 $173,409
Net loss from January 1, 1995 through June 28, 1995 (13,143)
Net change in amounts due to/from Schering Plough 11,272
--------
Excess of assets over liabilities at June 28, 1995 $171,538
========
</TABLE>
Management and advisory fees--Company
In connection with the Wesley Jessen Acquisition, the Company entered into an
agreement with Bain Capital, Inc., an affiliate of the Company's major
stockholder, for the provision of management and advisory services. Included in
marketing and administrative expense during the period from June 29, 1995
through December 31, 1995 and for the years ended December 31, 1996 and 1997 are
$0.5 million, $1.3 million and $2.1 million, respectively, of management fees
paid for the services provided pursuant to this agreement. In addition, if the
Company enters into any acquisition transactions, it must pay specified fees to
Bain Capital, Inc. based upon the purchase price. The Company paid Bain Capital,
Inc. fees of $0.7 million for services provided in structuring the Wesley Jessen
Acquisition, and $3.0 million in connection with the structuring of the Bank
Credit Agreement used to finance the Barnes-Hind Acquisition.
Promissory Note--Company
On May 7, 1997, Wesley Jessen Corporation, a wholly owned subsidiary of the
Company, loaned the Company's Chief Executive Officer ("CEO") $1.2 million in
exchange for an unsecured promissory note bearing interest at the rate of 8%,
interest payable quarterly. The note is due at the earlier of (i) May 9, 2002,
(ii) the date the CEO ceases to be employed by the Company, or (iii) the date
the CEO disposes of any of his common stock holdings in the company. For
purposes of the Offering (Note 1), the Company waived the requirement that the
CEO repay such loan pursuant to clause (iii) above.
56
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
15. Geographical information
Financial information for the Company by geographic area is as follows (in
thousands):
<TABLE>
<CAPTION>
Predecessor Company
---------------- -----------------------------------------------
January 1, June 29 through Year ended Year ended
through June 28, December 31, December 31, December 31,
1995 1995 1996 1997
---------------- --------------- ------------ ------------
<S> <C> <C> <C> <C>
Total assets:
United States (including territories) $177,260 $54,669 $115,890 $112,210
Europe 10,119 8,609 50,523 44,041
Canada 4,076 4,052 4,576 4,145
Japan - - 7,756 9,210
Other - - 1,855 3,470
-------- ------- -------- --------
$191,455 $67,330 $180,600 $173,076
======== ======= ======== ========
Net sales:
United States (including territories) $ 45,366 $49,198 $174,190 $246,619
Europe 6,549 6,066 30,255 59,466
Canada 2,330 2,720 6,028 9,217
Japan - - 3,922 17,878
Other - - 914 6,117
Elimination (3,226) (3,669) (58,557) (57,119)
-------- ------- -------- --------
$ 51,019 $54,315 $156,752 $282,178
======== ======= ======== ========
</TABLE>
Aggregate export sales, by geographic area, were as follows (in thousands):
<TABLE>
<CAPTION>
Predecessor Company
---------------- -----------------------------------------------
January 1, June 29 through Year ended Year ended
through June 28, December 31, December 31, December 31,
1995 1995 1996 1997
---------------- --------------- ------------ ------------
<S> <C> <C> <C> <C>
Europe $1,656 $ 1,559 $ 5,583 $ 5,629
Asia Pacific 2,873 3,630 12,787 19,146
Latin America 2,610 2,984 12,278 10,106
Africa and Middle East 488 1,933 3,287 3,093
------ ------- ------- -------
$7,627 $10,106 $33,935 $37,974
====== ======= ======= =======
</TABLE>
Transfer pricing
Transfers among the Company's subsidiaries are at selling prices that represent
the selling subsidiary's cost plus a profit margin established by management.
57
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
QUARTERLY INFORMATION
(in thousands, except per share amounts)
<TABLE>
<CAPTION>
March 28 June 28 September 27 December 31
------------- ------------- ------------- -------------
<S> <C> <C> <C> <C>
1997
Net Sales $ 64,071 $ 72,083 $ 75,235 $ 70,789
Operating income (loss) (6,972) 710 11,989 12,220
Net income (loss) (10,731) (371) 7,095 7,305
Basic Earnings (loss) per share (0.70) (0.02) 0.41 0.41
Diluted Earnings (loss) per share (0.64) (0.02) 0.37 0.38
Market price per share:
High $ 16.75 $ 25.88 $ 31.00 $ 39.00
Low $ 14.63 $ 13.00 $ 22.50 $ 26.75
March 28 June 28 September 27 December 31
------------- ------------- ------------- -------------
<S> <C> <C> <C> <C>
1996
Net Sales $ 30,147 $ 32,250 $ 33,651 $ 60,704
Operating income (loss) (1,865) 4,625 5,979 (10,513)
Net income (loss) (2,455) 5,979 4,337 (10,603)
Basic Earnings (loss) per share (0.17) 0.41 0.30 (0.72)
Diluted Earnings (loss) per share (0.17) 0.38 0.27 (0.72)
Market price per share:
High N/A N/A N/A N/A
Low N/A N/A N/A N/A
</TABLE>
58
<PAGE>
WESLEY JESSEN VISIONCARE, INC.
FINANCIAL STATEMENT SCHEDULE
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
<TABLE>
<CAPTION>
Additions
charged to
Beginning costs and Ending
balance expenses Deductions balance
---------- ------------ ---------- --------
<S> <C> <C> <C> <C>
Allowance for Doubtful Accounts
Period from January 1, 1995 through June 28, 1995.... $ 5,200 $ 1,450 $ (2,456) $ 4,194
Period from June 29, 1995 through December 31, 1995.. 5,342 (a) $ 861 $ (1,548) $ 4,655
Year ended December 31, 1996......................... $ 4,655 5,509 (b) $ (3,175) $ 6,989
Year ended December 31, 1997......................... $ 6,989 $ 2,476 $ (3,175) $ 6,290
Allowance for Sales Returns and Adjustments
Period from January 1, 1995 through June 28, 1995.... $15,810 $10,962 $(15,993) $10,779
Period from June 29, 1995 through December 31, 1995.. $10,779 $ 4,088 $ (7,642) $ 7,225
Year ended December 31, 1996......................... $ 7,225 14,999 (c) $(11,602) $10,622
Year ended December 31, 1997......................... $10,622 $ 2,416 $ (2,677) $10,361
</TABLE>
(a) Includes purchase accounting adjustment of $1,148 to adjust the
Predecessor's policy to that of the Company.
(b) Includes October 2, 1996 Barnes-Hind opening balance sheet account balance
of $3,476.
(c) Includes October 2, 1996 Barnes-Hind opening balance sheet account balance
of $2,622.
59
<PAGE>
REPORT OF INDEPENDENT ACCOUNTANTS ON
FINANCIAL STATEMENT SCHEDULE
To the Board of Directors and Stockholders
of Wesley Jessen VisionCare, Inc.
Our audits of the consolidated financial statements referred to in our report
dated September 17, 1996 (relating to the Wesley-Jessen contact lens business of
Schering-Plough Corporation) and our report dated February 20, 1998, (relating
to Wesley Jessen VisionCare, Inc.) also included an audit of the Financial
Statement Schedule listed in Item 14(a) of this Form 10-K. In our opinion, the
Financial Statement Schedule presents fairly, in all material respects, the
information set forth therein when read in conjunction with the related
consolidated financial statements.
PRICE WATERHOUSE LLP
Chicago, Illinois
February 20, 1998
60
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities and
Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized, on this ________
day of March, 1998.
WESLEY JESSEN VISIONCARE, INC.
By /s/ Kevin J. Ryan
-----------------
Kevin J. Ryan
President and Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1994, this
report has been signed below by the following persons on behalf of the
registrant in the capacities indicated on this _____ day of March, 1998.
Signature Capacity
--------- --------
/s/ Stephen G. Pagliuca Chairman of the Board
------------------------------
Stephen G. Pagliuca
/s/ Kevin J. Ryan President and Director (principal
------------------------------ executive officer)
Kevin J. Ryan
/s/ Edward J. Kelley Chief Financial Officer, Treasurer
------------------------------ and Director (principal financial
Edward J. Kelley officer)
/s/ Ronald J. Artale Vice President--Controller (principal
------------------------------ accounting officer)
Ronald J. Artale
/s/ Michael A. D'Amato Director
------------------------------
Michael A. D'Amato
/s/ Adam W. Kirsch Director
------------------------------
Adam W. Kirsch
/s/ Sol Levine Director
------------------------------
Sol Levine
/s/ John W. Maki Director
------------------------------
John W. Maki
/s/ John J. O'Malley Director
------------------------------
John J. O'Malley
61
<PAGE>
INDEX TO EXHIBITS
EXHIBIT INDEX
Exhibit No. Exhibit Description
----------- -------------------
2.1 Purchase and Sale Agreement, dated as of May 5, 1995,
between Schering Corporation and WJ Acquisition Corp.+(1)
2.2 Agreement for Purchase and Sale, dated as of July 5, 1996,
between the Company and Pilkington plc.+(1)
3.1(i) Amended and Restated Certificate of Incorporation.(2)
3.1(ii) Amended and Restated By-laws.(2)
4.1 Certificate representing shares of Common Stock, $0.01 par value
per share.(1)
4.2 Stockholders Agreement, dated October 22, 1996, among the
Company and the stockholders named therein.(1)
4.3 Amended and Restated Registration Agreement, dated as of October
22, 1996, between the Company and the stockholders named
therein.(1)
4.4 Credit Agreement, dated as of February 19, 1997 and as amended
as of September 10, 1997, among Wesley Jessen VisionCare, Inc.,
Wesley-Jessen Corporation, various lending institutions, and
Bankers Trust Company, as Agent.+(3)
4.5 Security Agreement, dated as of February 19, 1997, among Wesley
Jessen VisionCare, Inc., Wesley-Jessen Corporation, certain
other subsidiaries of Wesley Jessen VisionCare, Inc. and Bankers
Trust Company, as Collateral Agent.+(2)
4.6 Pledge Agreement, dated as of February 19, 1997, by Wesley
Jessen VisionCare, Inc., Wesley-Jessen Corporation and certain
other subsidiaries of Wesley Jessen VisionCare, Inc. in favor of
Bankers Trust Company, as Collateral Trustee and Agent.+(2)
4.7 Subsidiary Guaranty, dated as of February 19, 1997, made by each
subsidiary of Wesley-Jessen Corporation named therein and
Bankers Trust Company, as Agent.(2)
4.8 Subordinated seller's note, dated as of October 2, 1996, by
Wesley-Jessen Corporation in favor of Pilkington plc.(1)
10.1 Wesley Jessen VisionCare, Inc. 1997 Stock Incentive Plan.(2)
10.2 Wesley Jessen VisionCare, Inc. Non-Employee Director Stock
Option Plan.(2)
10.3 Amended and Restated Advisory Agreement, dated as of October 2,
1996, between Wesley-Jessen Corporation and Bain Capital,
Inc.(1)
10.4 Stock Purchase Agreement, dated as of June 28, 1995, among
Wesley-Jessen Holding, Inc. and the various purchasers named
therein.(1)
10.5 Agreement, dated as of December 21, 1992, between Wesley-Jessen
Corporation and Tech Medical Inc., regarding casting cups, as
amended.(1)
10.6 Employment Agreement, dated June 28, 1995, between the Company
and Kevin J. Ryan.(1)
10.7 Employment Agreement, dated June 28, 1995, between the Company
and Edward J. Kelley.(1)
10.8 Wesley-Jessen Holding, Inc. 1995 Stock Purchase and Option
Plan.(1)
10.9 Wesley-Jessen Holding, Inc. 1996 Stock Option Plan.(1)
10.10 Management Agreement, effective as of June 28, 1995 and dated as
of April 5, 1996, by and between the Company and Kevin J. Ryan
(with an attached schedule setting forth the terms of other
Named Executives).(1)
10.11 Indemnification Agreement, dated as of March 4, 1997 and
effective as of February 12, 1997, between Kevin J. Ryan and the
Company with an attached schedule listing the other officers and
directors who entered into such an agreement.(2)
10.12 Lease agreements relating to the Company's Southampton, United
Kingdom manufacturing facility.(1)
10.13 Lease agreements relating to the Company's San Diego, California
manufacturing facility.(1)
10.14 Wesley-Jessen Corporation Professional Incentive Program
(1996).(1)
10.15 Wesley Jessen VisionCare, Inc. Employee Stock Discount Purchase
Plan.(2)
10.16 Asset Purchase Agreement, dated as of January 24, 1997, by and
among Wesley-Jessen Corporation, PBH, Inc. and The Cooper
Companies, Inc.+(2)
10.17 Unsecured promissory note, dated as of May 7, 1997, by Kevin J.
Ryan in favor of Wesley-Jessen Corporation.(4)
11.1 Earnings Per Share.
21.1 Subsidiaries of the Company.(1)
23.1 Consent of Price Waterhouse LLP.
27.1 Financial Data Schedule.
________________
(1) Incorporated by reference to the applicable exhibit to the Registrant's
Registration Statement on Form S-1, Registration No. 333-17353.
(2) Incorporated by reference to the applicable exhibit to the Registrant's
Quarterly Report on Form 10-Q for the quarterly period ended March 31,
1997, File No. 0-22033.
(3) Incorporated by reference to the applicable exhibit to the Registrant's
Quarterly Report on Form 10-Q for the quarterly period ended September 27,
1997, File No. 0-22033.
(4) Incorporated by reference to the applicable exhibit to the Registrant's
Registration Statement on Form S-1, Registration No. 333-32493.
+ The Company agrees to furnish supplementally to the Commission a copy of
any omitted schedule or exhibit to such agreement upon request by
Commission.
62
<PAGE>
Exhibit 11.1
WESLEY JESSEN VISIONCARE, INC.
COMPUTATION OF EARNINGS (LOSS) PER SHARE
(in thousands, except per share amounts)
(Unaudited)
<TABLE>
<CAPTION>
June 29 Year Ended
through ------------ -----------
December 31, December 31, December 31,
1995 1996 1997
----------- ----------- -----------
<S> <C> <C> <C>
Computation of basic net income (loss) per share:
Net income (loss) $ (19,715) $ (2,742) $ 3,298
=========== =========== ===========
Weighted average common shares outstanding 14,416 14,638 16,898
Basic net income (loss) per share $ (1.37) $ (0.19) $ 0.20
=========== =========== ===========
Computation of diluted net income (loss) per share:
Net income (loss) $ (19,715) $ (2,742) $ 3,298
=========== =========== ===========
Weighted average common shares outstanding 14,416 14,638 16,898
Net additional shares issuable in connection with
stock options pursuant to the treasury stock method - - 1,553
----------- ----------- -----------
Diluted weighted average common shares outstanding 14,416 14,638 18,451
=========== =========== ===========
Diluted net income (loss) per share $ (1.37) $ (0.19) $ 0.18
=========== =========== ===========
Computation of supplemental net income per share:
Net income
As reported $ 3,298
Add: interest paid 953
Less: tax effect (324)
-----------
As adjusted $ 3,927
===========
Weighted average common shares outstanding 14,305
Shares to be issued 3,321
-----------
17,626
===========
Supplemental net income per share $ 0.22
===========
</TABLE>
<PAGE>
Exhibit 23.1
CONSENT OF INDEPENDENT ACCOUNTANTS
We hereby consent to the incorporation by reference in the Registration
Statements on Form S-8 (Nos. 333-28835, 333-28853, 333-29061 and 333-40139) of
Wesley Jessen VisionCare, Inc. of our reports dated February 20, 1998, September
17, 1996 and February 20, 1998 appearing on pages 30, 31 and 60 of this Form
10-K. We also consent to the incorporation by reference of our report for the
financial statement schedules, which appears on Page 60 of this Form 10-K.
Price Waterhouse, LLP
Chicago, Illinois
March 31, 1998
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JAN-01-1997
<PERIOD-END> DEC-31-1997
<CASH> 4,759
<SECURITIES> 0
<RECEIVABLES> 59,293
<ALLOWANCES> 16,651<F1>
<INVENTORY> 49,262
<CURRENT-ASSETS> 128,435
<PP&E> 22,774
<DEPRECIATION> 1,294
<TOTAL-ASSETS> 173,076
<CURRENT-LIABILITIES> 62,600
<BONDS> 0
0
0
<COMMON> 177
<OTHER-SE> 36,669
<TOTAL-LIABILITY-AND-EQUITY> 173,076
<SALES> 282,178
<TOTAL-REVENUES> 282,178
<CGS> 92,780
<TOTAL-COSTS> 265,093
<OTHER-EXPENSES> (862)
<LOSS-PROVISION> 4,892
<INTEREST-EXPENSE> 5,559
<INCOME-PRETAX> 12,388
<INCOME-TAX> 4,188
<INCOME-CONTINUING> 8,200
<DISCONTINUED> 0
<EXTRAORDINARY> (4,902)
<CHANGES> 0
<NET-INCOME> 3,298
<EPS-PRIMARY> 0.20
<EPS-DILUTED> 0.18
<FN>
<F1> ALLOWANCES NETTED AGAINST TRADE RECEIVABLES INCLUDE BOTH BAD DEBT RESERVES
AND SALES RETURN RESERVES.
</FN>
</TABLE>
